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2009 STEMI and PCI Focused Updates
Preamble
A primary challenge in the development of clinical practice
guidelines is keeping pace with the stream of new data on
which recommendations are based. In an effort to respond
promptly to new evidence, the American College of Cardi-
ology Foundation/American Heart Association (ACCF/AHA)
Task Force on Practice Guidelines has created a “focused
update” process to revise the existing guideline recommen-
dations that are affected by evolving data or opinion. Before
the initiation of this focused approach, periodic updates and
revisions of existing guidelines required up to 3 years to
complete. Now, however, new evidence will be reviewed in
an ongoing fashion to more efficiently respond to important
science and treatment trends that could have a major impact
on patient outcomes and quality of care. Evidence will be
reviewed at least twice a year, and updates will be initiated on
an as-needed basis as quickly as possible, while maintaining
the rigorous methodology that the ACCF and AHA have
developed during their 25 years of partnership.
These updated guideline recommendations reflect a con-
sensus of expert opinion after a thorough review primarily of
late-breaking clinical trials identified through a broad-based
vetting process as being important to the relevant patient
population, as well as a review of other new data deemed to
have an impact on patient care (see Section 1.1, Methodology
and Evidence Review, for details). This focused update is not
intended to represent an update based on a full literature
review from the date of the previous guideline publication.
Specific criteria/considerations for inclusion of new data
include the following:
● publication in a peer-reviewed journal;
● large randomized, placebo-controlled trial(s);
● nonrandomized data deemed important on the basis of
results that affect current safety and efficacy assumptions;
● strength/weakness of research methodology and findings;
● likelihood of additional studies influencing current findings;
● impact on current performance measure(s) and/or likeli-
hood of need to develop new performance measure(s);
● requests and requirements for review and update from the
practice community, key stakeholders, and other sources
free of relationships with industry or other potential bias;
● number of previous trials showing consistent results; and
● need for consistency with a new guideline or guideline revision.
In analyzing the data and developing updated recommen-
dations and supporting text, the focused update writing group
used evidence-based methodologies developed by the ACCF/
AHA Task Force on Practice Guidelines, which are described
elsewhere.1
The schema for classification of recommendations and
level of evidence is summarized in Table 1, which also
illustrates how the grading system provides an estimate of the
size of the treatment effect and an estimate of the certainty of
the treatment effect. Note that a recommendation with level
of evidence B or C does not imply that the recommendation
is weak. Many important clinical questions addressed in
guidelines do not lend themselves to clinical trials. Although
randomized trials may not be available, there may be a very
clear clinical consensus that a particular test or therapy is
useful and effective. Both the classification of recommenda-
tions and level of evidence listed in the focused updates are
based on consideration of the evidence reviewed in previous
iterations of the guideline and the focused update. Of note,
the implications of older studies that have informed recom-
mendations but have not been repeated in contemporary
settings are considered carefully.
The ACCF/AHA practice guidelines address patient popula-
tions (and healthcare providers) residing in North America. As
such, drugs that are not currently available in North America are
discussed in the text without a specific class of recommendation.
For studies performed in large numbers of subjects outside of
North America, each writing group reviews the potential impact
of different practice patterns and patient populations on the
treatment effect and on the relevance to the ACCF/AHA target
population to determine whether the findings should inform a
specific recommendation.
The ACCF/AHA practice guidelines are intended to assist
healthcare providers in clinical decision making by describ-
ing a range of generally acceptable approaches for the
diagnosis, management, and prevention of specific diseases
or conditions. The guidelines attempt to define practices that
meet the needs of most patients in most circumstances. The
ultimate judgment regarding care of a particular patient must
be made by the healthcare provider and patient in light of all
the circumstances presented by that patient. Thus, there are
circumstances in which deviations from these guidelines may
be appropriate. Clinical decision making should consider the
quality and availability of expertise in the area where care is
provided. These guidelines may be used as the basis for
regulatory or payer decisions, but the ultimate goals are
quality of care and serving the patient’s best interests.
Prescribed courses of treatment in accordance with these
recommendations are effective only if they are followed by
the patient. Because a lack of patient adherence may ad-
versely affect treatment outcomes, healthcare providers
should engage the patient in active participation with the
prescribed treatment.
The ACCF/AHA Task Force on Practice Guidelines makes
every effort to avoid actual, potential, or perceived conflicts
of interest that may arise as a result of industry relationships
or personal interests among the writing committee. Specifi-
cally, all members of the writing committee, as well as
reviewers of the document, are asked to disclose all such
relevant relationships pertaining to the trials and other evi-
dence under consideration (see Appendixes 1, 2, and 3). All
guideline recommendations require a confidential vote by the
writing group and must be approved by a consensus of the
members voting. Members who recused themselves from
voting are noted on the title page of this document. Members
must recuse themselves from voting on any recommendations
to which their relationships with industry and other entities
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apply. Writing group members who did not participate are not
listed as authors of this focused update. The work of the
writing group was supported exclusively by the ACCF and
AHA without commercial support. Writing group members
volunteered their time for this effort.
With the exception of the recommendations presented here,
the full-text guidelines remain current.2,3 Only the recommen-
dations from the affected section(s) of the full-text guidelines are
included in this focused update. Recommendations from any
section of a guideline affected by a change are presented with
notation as to whether they are new or have been modified;
however, recommendations that remain unchanged in each
section are not included in this focused update. When evidence
affects recommendations in more than 1 set of guidelines, those
guidelines are updated concurrently whenever possible.
The recommendations in this focused update will be
considered current until they are superseded by another
focused update or the full-text guidelines are revised. This
focused update is published in the December 1, 2009, issues
of the Journal of the American College of Cardiology and
Circulation as an update to the full-text guideline, and it is
also posted on the American College of Cardiology (ACC;
www.acc.org), AHA (my.americanheart.org), and Society for
Cardiovascular Angiography and Interventions (SCAI;
scai.org) World Wide Web sites.
Alice K. Jacobs, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines
1. Introduction
1.1. Methodology and Evidence Review
Late-breaking clinical trials presented at the 2007 and 2008
annual scientific meetings of the ACC, AHA, Transcatheter
Cardiovascular Therapeutics, the European Society of Cardi-
Table 1. Applying Classification of Recommendations and Level of Evidence
*Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as gender, age, history of diabetes, history of prior
myocardial infarction, history of heart failure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply that the recommendation is weak.
Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Even though randomized trials are not available, there may
be a very clear clinical consensus that a particular test or therapy is useful or effective.
†In 2003, the ACCF/AHA Task Force on Practice Guidelines developed a list of suggested phrases to use when writing recommendations. All guideline
recommendations have been written in full sentences that express a complete thought, such that a recommendation, even if separated and presented apart from
the rest of the document (including headings above sets of recommendations), would still convey the full intent of the recommendation. It is hoped that this will
increase readers’ comprehension of the guidelines and will allow queries at the individual recommendation level.
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ology, and the 2009 annual scientific sessions of the ACC
were reviewed by the standing guideline writing committee
along with the parent Task Force and other experts to identify
those trials and other key data that may impact guideline
recommendations. On the basis of the criteria/considerations
noted above, recent trial data and other clinical information were
considered important enough to prompt a focused update of the
ACC/AHA 2004 Guidelines for the Management of Patients
With ST-Elevation Myocardial Infarction and the ACC/AHA
2005 Guidelines for Percutaneous Coronary Intervention, inclu-
sive of their respective 2007 focused updates.2–5
The ST-elevation myocardial infarction (STEMI) and per-
cutaneous coronary intervention (PCI) writing groups to-
gether considered the following studies: Two meta-analyses,
“A Comparison of Abciximab and Small Molecule Glyco-
protein IIb/IIIa Inhibitors in Patients Undergoing Primary
Percutaneous Coronary Intervention,”6 and “Benefits From
Small Molecule Administration as Compared With Abcix-
imab Among Patients With ST-Segment Elevation Myo-
cardial Infarction Treated With Primary Angioplasty,”7
FINESSE (Facilitated PCI in Patients With ST-Elevation
Myocardial Infarction),8 the HORIZONS-AMI (Harmonizing
Outcomes With Revascularization and Stents in Acute Myo-
cardial Infarction),9 BRAVE-3 (Bavarian Reperfusion Alter-
natives Evaluation-3),10 MULTISTRATEGY (Multicentre
Evaluation of Single High-Dose Bolus Tirofiban Versus
Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent
in Acute Myocardial Infarction Study),11 ON-TIME 2 (On-
going Tirofiban in Myocardial Infarction Evaluation),12
TRITON-TIMI 38 (Trial to Assess Improvement in Thera-
peutic Outcomes by Optimizing Platelet Inhibition With
Prasugrel–Thrombolysis in Myocardial Infarction),13
TRANSFER-AMI (Trial of Routine ANgioplasty and Stent-
ing after Fibrinolysis to Enhance Reperfusion in Acute
Myocardial Infarction),14 CARESS-in-AMI (Combined Ab-
ciximab Reteplase Stent Study in Acute Myocardial Infarc-
tion),15 NICE-SUGAR (Normoglycemia in Intensive Care
Evaluation—Survival Using Glucose Algorithm Regula-
tion),16 TAPAS (Thrombus Aspiration during Percutaneous
coronary intervention in Acute myocardial infarction
Study),17 and EXPIRA (Thrombectomy With Export Catheter
in Infarct-Related Artery During Primary Percutaneous Cor-
onary Intervention).18 Additionally, the PCI writing group
considered the CARE (Cardiac Angiography in Renally
Impaired Patients),19 FAME (Fractional Flow Reserve versus
Angiography for Multivessel Evaluation) study,20 SYNTAX
(Synergy Between Percutaneous Intervention With Taxus and
Cardiac Surgery),21 Early ACS (Early versus Delayed, Pro-
visional Eptifibatide in Acute Coronary Syndromes),22 and
TIMACS (Timing of Intervention in Patients With Acute
Coronary Syndromes) studies.23 When considering the new
data for this focused update, the writing group faced the task
of weighing evidence from studies that had enrolled large
numbers of subjects outside North America. Although noting
that practice patterns and the rigor applied to data collection,
as well as the genetic makeup of subjects, may influence the
observed magnitude of a treatment’s effect, the writing group
believed the data were relevant to the formulation of recom-
mendations for management of STEMI and PCI in North
America. The writing group also notes that the AHA/ACCF
and the Heart Rhythm Society have published updated
recommendations for the standardization and interpretation of
the electrocardiogram with a separate section on acute
ischemia/infarction.24
To provide clinicians with a comprehensive set of data,
whenever possible, the exact event rates in various treatment
arms of clinical trials are presented to permit calculation of
the absolute risk difference and number needed to treat
(NNT) or harm; the relative treatment effects are described
either as odds ratio, relative risk (RR), or hazard ratio (HR)
depending on the format used in the original publication.
Along with all other statistical point estimates, the confidence
interval (CI) for those statistics are added when available.
Consult the full-text or executive summary versions of the
ACC/AHA 2004 Guidelines for the Management of Patients
With ST-Elevation Myocardial Infarction or the ACC/AHA/
SCAI 2005 Guidelines for Percutaneous Coronary Interven-
tion, as well as their respective 2007 focused updates, for
policy on clinical areas not covered by the present focused
update.2–5 Unchanged recommendations from previous itera-
tions of the guidelines are not listed in this document and
remain current policy. Individual recommendations updated
in this focused update will be incorporated into future
revisions of the full-text guidelines.
1.2. Organization of Committee and Relationships With
Industry and Other Entities
For this focused update, all members of the 2004 STEMI
guideline, 2007 STEMI focused update, 2005 PCI guideline,
and 2007 PCI focused update writing committees were
invited to participate; those who agreed (referred to as the
2009 Focused Update Writing Group) were required to
disclose all relationships with industry and other entities
relevant to the data under consideration. The policies used for
relationships with industry were those in effect at the initial
meeting of this committee, which included disclosure of
relationships 12 months prior to initiation and a chair with no
relevant relationships except in a situation where more than
one chair is named. In this circumstance, one chair will have
no relevant relationships and the other may have relation-
ships. Each recommendation required a confidential vote by
the writing group members before and after external review
of the document. Any writing group member with a relation-
ship with industry relevant to the recommendation was
recused from voting on that recommendation. The PCI
writing group included 2 representatives from SCAI.
1.3. Document Review and Approval
This document was reviewed by 3 official reviewers nomi-
nated by the ACCF and 4 official reviewers nominated by the
AHA, 1 official reviewer nominated by the SCAI, 6 review-
ers from the ACCF Interventional Council, 2 reviewers from
the ACCF Imaging Council, and 22 content reviewers. All
reviewer information on relationships with industry and other
entities was collected and distributed to the writing commit-
tee and is published in Appendix 3. This document was
approved for publication by the governing bodies of the
ACCF, the AHA, and the SCAI (specifically, the PCI portion
of the guideline).
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STEMI and PCI Focused Update Section
2. Recommendations for the Use of Glycoprotein
IIb/IIIa Receptor Antagonists
(See Table 2 and Appendix 4.)
2.1. Glycoprotein IIb/IIIa Receptor Antagonists
In considering the use of intravenous glycoprotein (GP)
IIb/IIIa receptor antagonists for STEMI, the writing group
noted that much of the evidence favoring the use of these
agents was established in the era before dual oral antiplatelet
therapy and largely by placebo-controlled comparisons. Con-
temporary management of STEMI patients involves a com-
plex array of antithrombotics, including dual oral antiplatelet
therapy (aspirin [acetylsalicylic acid; ASA] plus a thienopy-
ridine) and an anticoagulant. There is a paucity of trials
adequately powered for assessment of clinical end points that
have reevaluated the current relative role of intravenous GP
IIb/IIIa receptor antagonists with respect to other pharmacolog-
ical therapy in STEMI patients. Accordingly, a reevaluation of
the value of GP IIb/IIIa antagonists in STEMI is appropriate, but
the ability to draw definitive conclusions is limited.
At least 3 trials evaluated GP IIb/IIIa antagonists as
adjuncts to oral antiplatelet therapy in the setting of primary
PCI. The findings of these trials question whether GP IIb/IIIa
antagonists provide significant additional benefit to STEMI
patients who have received dual-antiplatelet therapy before
catheterization. In the BRAVE-3 study, 800 patients pres-
enting within 24 hours of a STEMI were pretreated with 600
mg of clopidogrel and then randomly assigned in a double-
blind manner to receive either abciximab or placebo in the
intensive care unit before being sent for PCI.10 The primary
end point was infarct size measured by single photon emis-
sion computed tomography before hospital discharge. At 30
days, the composite of death, recurrent myocardial infarction
(MI), stroke, or urgent revascularization of the infarct-related
artery was not significantly different in the 2 groups (abcix-
imab 5%, placebo 3.8%; 95% CI 0.7 to 2.6; P0.4). There
was no significant difference in infarct size or major bleeding.
ON-TIME 2 was a randomized, placebo-controlled, multi-
center European trial that included 491 patients receiving
high-dose tirofiban and 493 receiving placebo within a
median of 76 minutes from onset of symptoms.12 Patients
receiving high-dose tirofiban (25 mcg/kg bolus followed by
0.15 mcg/kg per min for 18 hours) at first medical contact
before transport for primary PCI were also treated with
unfractionated heparin (UFH; 5000 U), clopidogrel (600 mg),
and ASA. Patients in the high-dose tirofiban group had
improved ST-segment resolution (primary end point) before
and 1 hour after PCI (P0.003) compared with those receiv-
ing placebo (NNT100). However, there was no significant
difference in Thrombolysis In Myocardial Infarction (TIMI)
grade 3 flow or blush grade and no significant difference in
major bleeding or minor bleeding. There was no significant
difference in death, recurrent MI, or urgent target-vessel
revascularization (TVR) between the tirofiban and placebo
groups at 30 days.25
In the HORIZONS-AMI trial,9 patients undergoing pri-
mary PCI for STEMI were randomized to treatment with
UFH plus a GP IIb/IIIa receptor antagonist (abciximab or
double-bolus eptifibatide) or to bivalirudin alone with provi-
sional IIb/IIIa. Aspirin and a thienopyridine were adminis-
tered before catheterization. (See the full discussion of the
trial under Section 4, Recommendations for the Use of
Parenteral Anticoagulants.) Seven hundred fifty-seven of the
1661 patients who received UFH received a double bolus of
eptifibatide and infusion, whereas 53 of 1661 in the bivaliru-
din arm received eptifibatide. At 30 days, rates of major
bleeding and total adverse events were higher among patients
treated with GP IIb/IIIa antagonists and heparin than among
those given bivalirudin alone.
Two meta-analyses of randomized trials were published
that compared small-molecule GP IIb/IIIa antagonists with
abciximab in STEMI patients undergoing primary PCI.6,7 In
each case, there was no statistically significant difference in
30-day mortality, reinfarction, or major TIMI bleeding, and
there was no significant difference in death or reinfarction at
8 months between groups. There was also no statistically
significant difference in postprocedural TIMI flow grade 3 or
ST-segment resolution. On the basis of these studies, the
present writing group judged that the totality of evidence
indicates that the various GP IIb/IIIa antagonists demonstrate
similar effectiveness in the setting of primary PCI.
MULTISTRATEGY was an open-label, multicenter, ran-
domized European trial with a 2-by-2 factorial design that
Table 2. Recommendations for the Use of Glycoprotein IIb/IIIa Receptor Antagonists
2004/2005/2007 Recommendations: 2004 STEMI
Guideline Section 6.3.1.6.8.2.3; Also 2005 PCI
Guideline Section 6.2.2 2009 Joint STEMI/PCI Focused Update Recommendations Comments
Class IIa
1. It is reasonable to start treatment with abciximab
as early as possible before primary PCI (with or
without stenting) in patients with STEMI. (Level of
Evidence: B)
1. It is reasonable to start treatment with glycoprotein IIb/IIIa
receptor antagonists (abciximab9,11 Level of Evidence: A,
tirofiban11,12 Level of Evidence: B or eptifibatide6,7,9 Level of
Evidence: B) at the time of primary PCI (with or without stenting)
in selected patients with STEMI.
Modified recommendation
(class of
recommendation
changed from IIb to IIa
for tirofiban and
eptifibatide).
Class IIb
1. Treatment with tirofiban or eptifibatide may be
considered before primary PCI (with or without
stenting) in patients with STEMI. (Level of
Evidence: C)
1. The usefulness of glycoprotein IIb/IIIa receptor antagonists (as part
of a preparatory pharmacological strategy for patients with STEMI
before their arrival in the cardiac catheterization laboratory for
angiography and PCI) is uncertain.8,10 (Level of Evidence: B)
Modified recommendation
(text modified; level of
evidence changed from
C to B).
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randomized 745 STEMI patients undergoing primary PCI to
high-dose bolus tirofiban versus abciximab infusion and
sirolimus-eluting stent versus bare-metal stent (BMS).11 The
prespecified primary end points were the achievement of 50%
resolution of ST-segment elevation at 90 minutes after PCI,
powered for noninferiority, and the rate of major adverse
cardiac events (MACE) at 8 months, powered for superiority.
All patients received ASA at the usual doses, clopidogrel 300
mg orally then 75 mg per day, and UFH. There was a similar
rate of at least 50% ST-segment resolution at 90 minutes after
primary PCI with abciximab and tirofiban (RR 1.020; 97.5%
CI 0.958 to 1.086; P0.001 for noninferiority). Rates of
MACE, including all-cause death, clinical reinfarction, or
TVR, and hemorrhagic (major and minor bleeding) compli-
cations were similar. The incidence of severe or moderate
thrombocytopenia was more common with abciximab than
with tirofiban (4.0% versus 0.8%, P0.004).
In an analysis of the predictors of stent thrombosis after
primary PCI in acute MI presented at the 2009 ACC Scien-
tific Sessions, titled “Predictors of Stent Thrombosis After
Primary Angioplasty in Acute Myocardial Infarction: The
HORIZONS-AMI Trial,”69 there was no significant differ-
ence in the 1-year rate of stent thrombosis with the heparin
plus GP IIb/IIIa receptor antagonists compared with eptifi-
batide and abciximab (3.6% versus 2.8%, P0.93), which
suggests that eptifibatide has the same impact as abciximab
on stent thrombosis incidence.
One investigation, FINESSE, addressed the issue of timing
of GP IIb/IIIa antagonist administration. This double-blind,
randomized, placebo-controlled study of 2453 patients with
STEMI explored the use of pre-PCI treatment with a half-
dose fibrinolytic agent plus abciximab, pre-PCI abciximab
alone, and abciximab at the time of PCI.8 The primary end
point was the composite of death due to all causes, ventricular
fibrillation that occurred more than 48 hours after random-
ization, cardiogenic shock, and congestive heart failure dur-
ing the first 90 days after randomization. The results of the
trial are discussed in Section 5.1, Triage and Transfer for PCI.
This trial showed no benefit (and a tendency toward excess
bleeding) with prehospital abciximab compared with abcix-
imab at the time of PCI. The writing group concluded there
was no benefit of administration of abciximab before primary
PCI, alone or in combination with reteplase. On the basis of
this trial and ON-TIME 2, the writing group concluded that
the use of GP IIb/IIIa antagonists before primary PCI is of
uncertain benefit.
Given the results of the studies cited above, the writing
group concluded that in the setting of dual-antiplatelet ther-
apy with UFH or bivalirudin as the anticoagulant, current
evidence indicates that adjunctive use of a GP IIb/IIIa
antagonist can be useful at the time of primary PCI but cannot
be recommended as routine therapy. These agents might
provide more benefit in selective use, for example, for the
patient with a large thrombus burden or for patients who have
not received adequate thienopyridine loading.
3. Recommendations for the Use of
Thienopyridines
(See Table 3 and Appendix 4.)
3.1. Thienopyridines
Since the publication of the last guidelines,4,5 evidence has
emerged about prasugrel, a thienopyridine that achieves
greater inhibition of platelet aggregation than clopidogrel.27
The pivotal trial for prasugrel, TRITON-TIMI 38, focused on
patients with ACS who were referred for PCI.
TRITON-TIMI 38 randomly assigned 13 608 patients with
moderate- to high-risk ACS, 3534 of whom had STEMI, to
receive prasugrel (6813 patients received a 60-mg loading
dose and a 10-mg daily maintenance dose) or clopidogrel
(6795 patients received a 300-mg loading dose and a 75-mg
daily maintenance dose) for an average follow-up of 14.5
months. Aspirin was prescribed within 24 hours of PCI.
Clinical end points were assessed at 30 and 90 days and then
every 3 to 15 months.27
Prasugrel was associated with a significant 2.2% absolute
reduction and a 19% relative reduction in the primary
efficacy end point, a composite of the rate of death due to
cardiovascular causes (including arrhythmia, congestive heart
failure, shock, and sudden or unwitnessed death), nonfatal
MI, or nonfatal stroke during the follow-up period. The
primary efficacy end point occurred in 9.9% of patients
receiving prasugrel and 12.1% of patients receiving clopi-
dogrel (HR for prasugrel versus clopidogrel 0.81; 95% CI
0.73 to 0.90; P0.001). A significant reduction in the
primary end point was seen in the prasugrel group by the first
prespecified time point, which was 3 days (4.7% in the
prasugrel group versus 5.6% in the clopidogrel group; HR
0.82; 95% CI 0.71 to 0.96; P0.01), and persisted throughout
the follow-up period. From Day 3 to the end of the study, the
primary end point had occurred in 5.6% of patients receiving
prasugrel and in 6.9% of patients receiving clopidogrel (HR
0.80; 95% CI 0.70 to 0.93; P0.003). Prasugrel decreased
cardiovascular death, MI, and stroke by 138 events
(NNT46).27 The rate of MI with subsequent death due to
cardiovascular causes was also reduced in the prasugrel group
(P0.02). The difference in the primary end point was
largely related to the difference in rates of nonfatal MI (7.3%
for prasugrel versus 9.5% for clopidogrel; HR 0.76; 95% CI
0.67 to 0.85; P0.001). There were no significant differences
in the 2 treatment groups in the rates of stroke or of death due
to cardiovascular causes not preceded by recurrent MI (at 15
months, the nonfatal stroke rate was 1.0% for both prasugrel
and clopidogrel; HR for prasugrel1.02; CI 0.71 to 1.45;
P0.93; the rate of deaths due to cardiovascular causes not
preceded by recurrent MI was 2.1% for prasugrel versus 2.4%
for clopidogrel; HR 0.89; CI 0.70 to 1.12; P0.31). There
were significant reductions in the rates of ischemic events in
the prasugrel group compared with the clopidogrel group:
Rates of MI were 7.4% for prasugrel versus 9.7% for
clopidogrel (P0.001); urgent TVR rates were 2.5% for
prasugrel versus 3.7% for clopidogrel (P0.001); and rates
of stent thrombosis were 1.1% for prasugrel versus 2.4% for
clopidogrel (HR 0.48; 95% CI 0.36 to 0.64; P0.001).
Prasugrel was associated with a significant increase in the
rate of bleeding, notably, TIMI major hemorrhage, which was
observed in 2.4% of patients taking prasugrel and in 1.8% of
patients taking clopidogrel (HR for prasugrel versus clopidogrel
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Table 3. Recommendations for the Use of Thienopyridines
STEMI Recommendations PCI Recommendations 2009 Joint STEMI/PCI Focused Update Recommendations
Comments (All Modified
Recommendations Are for
Patients With ACS)
Class I
2004 STEMI Guidelines,
Section 7.4.4
2007 PCI Update, Table 14
4. For patients who have undergone
diagnostic cardiac catheterization
and for whom PCI is planned,
clopidogrel should be started and
continued for at least 1 month
after bare metal stent
implantation and for several
months after drug-eluting stent
implantation (3 months for
sirolimus, 6 months for
paclitaxel) and for up to 12
months in patients who are not
at high risk for bleeding. (Level
of Evidence: B)
4. A loading dose of clopidogrel,* generally
600 mg, should be administered before
or when PCI is performed. (Level of
Evidence: C) In patients undergoing PCI
within 12 to 24 hours of receiving
fibrinolytic therapy, a clopidogrel oral
loading dose of 300 mg may be
considered. (Level of Evidence: C)
1. A loading dose of thienopyridine is recommended for STEMI patients for
whom PCI is planned. Regimens should be 1 of the following:
a. At least 300 to 600 mg of clopidogrel† should be given as early as
possible before or at the time of primary or nonprimary PCI. (Level of
Evidence: C)
b. Prasugrel 60 mg should be given as soon as possible for primary
PCI.26,27 (Level of Evidence: B)
c. For STEMI patients undergoing nonprimary PCI, the following
regimens are recommended:
(i) If the patient has received fibrinolytic therapy and has been given
clopidogrel, clopidogrel should be continued as the thienopyridine
of choice (Level of Evidence: C);
(ii) If the patient has received fibrinolytic therapy without a
thienopyridine, a loading dose of 300 to 600 mg‡ of clopidogrel
should be given as the thienopyridine of choice (Level of
Evidence: C);
(iii) If the patient did not receive fibrinolytic therapy, either a loading
dose of 300 to 600 mg of clopidogrel should be given or, once
the coronary anatomy is known and PCI is planned, a loading
dose of 60 mg of prasugrel should be given promptly and no
later than 1 hour after the PCI.26,27 (Level of Evidence: B)
Modified recommendation
(changed text).
5. For all post-PCI stented patients receiving
a DES, clopidogrel 75 mg daily should be
given for at least 12 months if patients
are not at high risk of bleeding. For
post-PCI patients receiving a BMS,
clopidogrel should be given for a
minimum of 1 month and ideally up to
12 months (unless the patient is at
increased risk of bleeding; then it should
be given for a minimum of 2 weeks).
(Level of Evidence: B)
2. The duration of thienopyridine therapy should be as follows:
a. In patients receiving a stent (BMS or drug-eluting stent [DES]) during
PCI for ACS, clopidogrel 75 mg daily†27–29 (Level of Evidence: B) or
prasugrel 10 mg daily§27 (Level of Evidence: B) should be given for
at least 12 months;
b. If the risk of morbidity because of bleeding outweighs the anticipated
benefit afforded by thienopyridine therapy, earlier discontinuation
should be considered. (Level of Evidence: C)
Modified recommendation
(pertains to STEMI and
unstable angina
UA/non-STEMI
NSTEMI based on
TRITON-TIMI 38).
2007 STEMI Update, Section 9
2. In patients taking clopidogrel in
whom CABG is planned, the drug
should be withheld for at least 5
days and preferably for 7 days
unless the urgency for
revascularization outweighs the
risks of excess bleeding. (Level
of Evidence: B)
3. In patients taking a thienopyridine in whom CABG is planned and can
be delayed, it is recommended that the drug be discontinued to allow
for dissipation of the antiplatelet effect. (Level of Evidence: C) The
period of withdrawal should be at least 5 days in patients receiving
clopidogrel2,30 (Level of Evidence: B) and at least 7 days in patients
receiving prasugrel†27 (Level of Evidence: C), unless the need for
revascularization and/or the net benefit of the thienopyridine outweighs
the potential risks of excess bleeding.31 (Level of Evidence: C)
Modified recommendation
(added prasugrel).
Class IIa
2004 STEMI Guidelines, Section
7.4.4
2007 PCI Update, Table 14
1. If clopidogrel is given at the time of
procedure, supplementation with GP
IIb/IIIa receptor antagonists can be
beneficial. (Level of Evidence: B)
Deleted recommendation
2. For patients with an absolute
contraindication to aspirin, it is
reasonable to give a 300-mg to 600-mg
loading dose of clopidogrel, administered
at least 6 hours before PCI, and/or GP
IIb/IIIa antagonists, administered at the
time of PCI. (Level of Evidence: C)
Deleted recommendation
Class IIb
2004 STEMI Guidelines, Section
7.4.4
2007 PCI Update, Table 14
1. Continuation of clopidogrel therapy
beyond 1 year may be considered in
patients undergoing DES placement.
(Level of Evidence: C)
1. Continuation of clopidogrel or prasugrel§ beyond 15 months may be
considered in patients undergoing DES placement.27 (Level of Evidence: C)
Modified recommendation
(changed text).
(Continued)
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1.32; 95% CI 1.03 to 1.68, P0.03), which represented an
increase in the relative rate of major bleeding of 32%. From the
standpoint of safety, prasugrel was associated with an in-
crease of 35 TIMI major and non–coronary artery bypass
graft bleeds (number needed to harm167).27 Also, greater
rates of life-threatening bleeding were evident in the prasug-
rel group than in the clopidogrel group: 1.4% versus 0.9%,
respectively (HR for prasugrel 1.52; 95% CI 1.08 to 2.13;
P0.01), which included nonfatal bleeding (1.1% versus
0.9%; HR for prasugrel 1.25; 95% CI 0.87 to 1.81;
P0.23) and fatal bleeding (0.4% versus 0.1%; HR for
prasugrel 4.19; 95% CI 1.58 to 11.11; P0.002). In the
few patients who underwent coronary artery bypass graft
(CABG), TIMI major bleeding through 15 months was also
greater with prasugrel than with clopidogrel (13.4% versus
3.2%, respectively; HR for prasugrel 4.73; 95% CI 1.90 to
11.82; P0.001).27 Despite the increase in bleeding, the
net clinical-benefit end point, which included all-cause
mortality, ischemic events, and major bleeding events,
favored prasugrel.27
Prasugrel showed superior efficacy in major prespecified
subgroups in the overall ACS population. The benefit tended to
be greater among the 3146 patients with diabetes (12.2% of
whom had the primary end point in the prasugrel group versus
17.0% in the clopidogrel group; HR 0.70; 95% CI 0.58 to 0.85;
P0.001) than among the 10 462 patients without diabetes
(9.2% of whom had the primary end point in the prasugrel group
versus 10.6% in the clopidogrel group; HR 0.86; 95% CI 0.76 to
0.98; P0.02). The rate of definite or probable stent thrombosis
was significantly reduced in the prasugrel group compared with
the clopidogrel group, as noted.27
A post hoc analysis suggested there were 3 subgroups of
ACS patients who did not have a favorable net clinical benefit
(defined as the rate of death due to any cause, nonfatal MI,
nonfatal stroke, or non–CABG-related nonfatal TIMI major
bleeding) from the use of prasugrel or who had net harm:
Patients with a history of stroke or transient ischemic attack
(TIA) before enrollment had net harm from prasugrel (HR
1.54; 95% CI 1.02 to 2.32; P0.04), patients 75 years of age
and older had no net benefit from prasugrel (HR 0.99; 95% CI
0.81 to 1.21; P0.92); and patients with a body weight of less
than 60 kg had no net benefit from prasugrel (HR 1.03; 95%
CI 0.69 to 1.53; P0.89). In both treatment groups, patients
with at least 1 of these risk factors had higher rates of
bleeding than those without them.27 A pharmacokinetic anal-
ysis showed greater exposure to the active metabolite of
prasugrel for patients who weighed less than 60 kg and who
were 75 years old or older.38
The US Food and Drug Administration (FDA) approved
prasugrel in July 2009 and incorporated the aforementioned
subgroup findings into its labeling by citing a contraindica-
tion against prasugrel use in patients with a history of TIA or
stroke and active pathological bleeding. The FDA further
recommends that consideration be given to lowering the
maintenance dose of prasugrel to 5 mg in patients who weigh
less than 60 kg, with a note that the effectiveness and safety
of the 5-mg dose have not been studied prospectively to date.
The FDA labeling information includes a general warning
against the use of prasugrel in patients older than 75 years of
age because of concerns of an increased risk of fatal and
intracranial bleeding and uncertain benefit, except in high-
risk situations (patients with diabetes or a history of prior
Table 3. Continued
STEMI Recommendations PCI Recommendations 2009 Joint STEMI/PCI Focused Update Recommendations
Comments (All Modified
Recommendations Are for
Patients With ACS)
Class III
1. In STEMI patients with a prior history of stroke and transient ischemic
attack for whom primary PCI is planned, prasugrel is not recommended
as part of a dual-antiplatelet therapy regimen. (Level of Evidence: C)
New recommendation
*Available data for prasugrel use are for PCI for acute coronary syndrome (ACS) and not elective PCI. Recommendations for elective PCI with clopidogrel use are
not being updated in this guideline focused update.
†The optimum loading dose of clopidogrel has not been established. Randomized trials establishing its efficacy and providing data on bleeding risks used a loading
dose of 300 mg orally followed by a daily oral dose of 75 mg.26,27 Higher oral loading doses such as 600 mg or more than 900 mg36 of clopidogrel more rapidly inhibit
platelet aggregation and achieve a higher absolute level of inhibition of platelet aggregation, but the additive clinical efficacy and safety of higher oral loading doses
have not been rigorously established. The necessity for giving a loading dose of clopidogrel before PCI is driven by the pharmacokinetics of clopidogrel, for which
several hours are required to achieve desired levels of platelet inhibition. For post-PCI patients receiving a stent (BMS or DES), a daily maintenance dose should be
given for at least 12 months and for up to 15 months unless the risk of bleeding outweighs the anticipated net benefit afforded by a thienopyridine.
‡Clopidogrel loading dose after fibrinolytic therapy: For patients given fibrin- and non–fibrin-specific fibrinolytic drugs who are undergoing PCI within 24 hours, 300
mg; for patients given a fibrin-specific fibrinolytic undergoing PCI after more than 24 hours, 300 to 600 mg; for patients given a non–fibrin-specific fibrinolytic
undergoing PCI between 24 and 48 hours, 300 mg; for patients given a non–fibrin-specific fibrinolytic undergoing PCI after 48 hours, 300 to 600 mg.
§Patients weighing60 kg have an increased exposure to the active metabolite of prasugrel and an increased risk of bleeding on a 10-mg once-daily maintenance
dose. Consideration should be given to lowering the maintenance dose to 5 mg in patients who weigh 60 kg. The effectiveness and safety of the 5-mg dose have
not been studied prospectively. For post-PCI patients receiving a stent (BMS or DES), a daily maintenance dose should be given for at least 12 months and for up
to 15 months unless the risk of bleeding outweighs the anticipated net benefit afforded by a thienopyridine. Do not use prasugrel in patients with active pathological
bleeding or a history of transient ischemic attack or stroke. In patients 75 years of age, prasugrel is generally not recommended because of the increased risk of
fatal and intracranial bleeding and uncertain benefit, except in high-risk situations (patients with diabetes or a history of prior MI) in which its effect appears to be
greater and its use may be considered. Do not start prasugrel in patients likely to undergo urgent CABG. When possible, discontinue prasugrel at least 7 days before
any surgery. Additional risk factors for bleeding include body weight60 kg, propensity to bleed, and concomitant use of medications that increase the risk of bleeding
(eg, warfarin, heparin, fibrinolytic therapy, or chronic use of nonsteroidal anti-inflammatory drugs).
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MI), in which case its effect appears to be greater and its use
may be considered.37
In focusing specifically on patients with STEMI, the
primary composite end point of cardiovascular death, nonfa-
tal MI, or nonfatal stroke was significantly reduced in patients
assigned to prasugrel at 30 days compared with patients who
received clopidogrel (6.5% versus 9.5%; HR 0.68; 95% CI
0.54 to 0.87; P0.0017), and this trend persisted to 15
months (HR 0.79; 95% CI 0.65 to 0.97; P0.0221).13
Furthermore, in the STEMI group, the key secondary end
point of cardiovascular death, MI, or urgent TVR was
significantly reduced with prasugrel at 30 days (P0.0205)
and 15 months (P0.0250).13 At 30 days and 15 months, the
individual end points of cardiovascular death and MI, as well
as stent thrombosis, were reduced with prasugrel.13
The interaction testing for efficacy and safety showed no
significant difference in bleeding risk regardless of the type
of ACS (eg, UA/NSTEMI versus STEMI). Thus, the STEMI
results for efficacy and safety are consistent with the main
results of the trial. In a post hoc analysis of patients with
anterior MI, event rates at 15 months for the primary end
point were lower with prasugrel (9.8% for prasugrel versus
16.3% for clopidogrel; HR 0.57; 95% CI 0.42 to 0.78;
P0.0003). In patients with nonanterior MI, treatment effects
did not differ for the primary end point (10.1% for prasugrel
versus 9.9% for clopidogrel; HR 1.02; 95% CI 0.78 to 1.34;
P0.8749). The test for heterogeneity of the effect of
prasugrel was significant (P0.0053), which suggests that
the benefit might vary by the location of the MI. Data were
consistent in both the primary and secondary PCI
subgroups.13
The writing group weighed the current data regarding the
use of thienopyridine therapy in patients who remain hospi-
talized after STEMI and are candidates for CABG and
retained the 2007 focused update recommendation of empiric
discontinuation of clopidogrel therapy for at least 5 days and
at least 7 days in patients receiving prasugrel before planned
CABG.2,27,30
Platelet function testing to determine the degree of platelet
inhibition39 may be used, and if platelet function has normalized,
CABG may be performed at an earlier time. Additionally, other
strategies of platelet inhibition (GP IIb/IIIa receptor antagonists)
may be used if recurrent ischemia is a concern during the waiting
period for CABG. Ultimately, the patient’s clinical status will
determine the risk-to-benefit ratio of CABG compared with
awaiting restoration of platelet function.
The results of TRITON-TIMI 38 influenced dosing recom-
mendations for loading and chronic thienopyridine therapy
with prasugrel. Sixty milligrams of prasugrel is now recom-
mended as a loading dose for primary PCI in STEMI. For
secondary PCI in those patients who have recurrent ischemia
or other reasons for planned intervention during their course
of treatment, 60 mg of prasugrel may be given after the
coronary anatomy has been identified (to avoid dosing those
patients who require CABG) either before, during, or within
1 hour of PCI.27 Furthermore, 10 mg of prasugrel may be
used in addition to ASA for chronic dual-antiplatelet
therapy.27
Determination of patient groups that should be considered
for continuation of dual-antiplatelet treatment beyond 12
months is based on patient-level factors (eg, age, history of
bleeding) and lesion characteristics (eg, bifurcation, small-
diameter vessel).28
In previous studies of patients with prior stroke or TIA, use
of dual-antiplatelet therapy has been associated with an
increased risk of adverse outcomes, notably intracranial
bleeding, compared with single-antiplatelet therapy. In the
MATCH (Management of Atherothrombosis With Clopi-
dogrel in High-Risk Patients With TIA or Stroke) trial40 in
which patients with prior stroke or TIA and additional risk
factors (n7599) were allocated to clopidogrel 75 mg or
combination therapy with clopidogrel 75 mg plus ASA 75 mg
per day, there was no significant benefit of combination
therapy compared with clopidogrel alone in reducing the
primary outcome of the composite of ischemic stroke, MI,
vascular death, or rehospitalization due to ischemic events, or
any of the secondary outcomes. The risk of major hemorrhage
was significantly increased in the combination-therapy group
compared with those given clopidogrel alone, with a 1.3%
absolute increase in life-threatening bleeding. Although clo-
pidogrel plus ASA is recommended over ASA alone for
patients with ACS,41–43 the results of MATCH do not suggest
a similar risk-benefit ratio for stroke and TIA survivors. The
AHA/American Stroke Association’s Guidelines for Preven-
tion of Stroke in Patients With Ischemic Stroke or Transient
Ischemic Stroke contain a Class III recommendation for the
use of ASA in combination with clopidogrel in patients with
prior stroke or TIA.44 On the other hand, a post hoc analysis
from the CHARISMA (Clopidogrel for High Atherothrom-
botic Risk and Ischemic Stabilization, Management, and
Avoidance) trial, which included 9478 patients, suggested
that patients with documented prior MI, ischemic stroke, or
symptomatic peripheral artery disease derive benefit from
dual-antiplatelet therapy with clopidogrel plus ASA.45 Al-
though MATCH and CHARISMA did not involve STEMI
patients, the writing group recommended weighing the ben-
efits and risks of prescribing clopidogrel and ASA in patients
with a recent history of TIA or stroke. Given prasugrel’s
greater tendency to cause intensive inhibition of platelet
aggregation in general and the findings of increased levels of
bleeding compared with clopidogrel in this population, the
use of prasugrel as part of a dual-antiplatelet therapy regimen
in patients with prior stroke or TIA is contraindicated.37
3.1.1. Additional Thienopyridine Information
Although clopidogrel in combination with ASA has been
shown to reduce recurrent coronary events in the posthospi-
talized ACS population,32,43,46 the response to clopidogrel
varies among patients, and clopidogrel resistance has been
observed.43 Information is accumulating about the variations
in the antiplatelet effect of clopidogrel in patients with
loss-of-function alleles in the gene encoding CYP450
2C19.32,46–50 These patients form a subgroup in which failure
of clopidogrel effectiveness has been linked to adverse
clinical outcomes.30,47–51 In TRITON-TIMI 38 and 3 of the
cohort studies,47,49,52 patients who were carriers of a reduced-
function CYP450 2C19 allele had significantly lower levels
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of the active metabolite of clopidogrel, diminished platelet
inhibition, and increased rates of cardiovascular events (eg,
death, MI, stroke), including stent thrombosis,53 compared
with the extensive metabolizers.54 In another cohort study
with 2208 patients,50 the increased event rate was observed
only in poor metabolizers. (Prasugrel has a higher level of
inhibition of platelet aggregation than clopidogrel and a more
rapid onset of action.55 Its metabolism is not affected by the
2C19 allele variant.56)
Accordingly, the effective clopidogrel dose for an individ-
ual undergoing PCI for STEMI may not be known. A large
randomized trial57 is attempting to determine whether adjust-
ment of clopidogrel therapy on the basis of platelet function
testing with a point-of-care assay safely improves outcomes
after PCI with DES. As noted in the drug dosing table
(Appendix 4), the current recommended loading dose for
clopidogrel is uncertain. In addition, a period of several hours
is required to metabolize clopidogrel to its active metabolite,
which leaves a window of time during which there is a
reduced level of effectiveness even in responders.
With regard to clopidogrel loading for PCI after a patient
has received fibrinolytic therapy, there are no studies that
have formally tested a 600-mg (or higher) clopidogrel loading
dose administered with fibrinolytic treatment. The only study
that tested any clopidogrel dose with a fibrinolytic was the
CLARITY-TIMI 28 (Clopidogrel as Adjunctive Reperfusion
Therapy–Thrombolysis in Myocardial Infarction 28) study,
which randomized 3491 patients 75 years of age and younger
who were receiving fibrinolytic therapy within 12 hours of
STEMI to clopidogrel (300-mg oral loading dose; 75-mg oral
daily maintenance dose) or placebo.58 As described in the
2007 STEMI focused update,4 patients who received clopi-
dogrel had a reduced rate of an occluded infarct artery,
accomplished by preventing infarct-related reocclusion rather
than by facilitating early reperfusion.
When considering a loading dose of clopidogrel for PCI after
a patient has received a fibrinolytic agent, the available level of
evidence is limited (Level of Evidence: C), and consensus
opinion suggests it is dependent on how many hours have
elapsed since fibrinolytic therapy was administered before PCI.
For patients who have received any fibrinolytic agent and
subsequently proceed to PCI within 24 hours, a dose of 300 mg
of clopidogrel as a loading dose is suggested. If the patient
received a fibrin-specific fibrinolytic agent and then proceeds to
PCI after 24 hours has elapsed, a loading dose of 300 to 600 mg
may be considered. If at least 48 hours has elapsed after
treatment with a non–fibrin-specific fibrinolytic agent, a dose of
300 to 600 mg may be considered.
Prasugrel has not been studied in patients who have
received fibrinolytic therapy. Thus, for STEMI patients un-
dergoing nonprimary PCI who received prior fibrinolytic
therapy without a thienopyridine, only a loading dose with
clopidogrel should be given as the thienopyridine of choice.
3.1.2. Choice of Thienopyridine for PCI in STEMI
The guidelines do not endorse explicitly one of the thienopy-
ridines over the other. There were several reasons for this
decision. Although the composite efficacy end point favored
prasugrel, driven predominantly by a difference in nonfatal
MIs, with deaths and nonfatal strokes being similar, bleeding
was increased in the prasugrel group.27 In addition, the
comparison of the 2 drugs is based on a single large trial.
Also, the loading dose of clopidogrel in TRITON-TIMI 38
was lower than is currently recommended in these guidelines.
Furthermore, there are some emerging studies that suggest
there may be some patients who are resistant to clopidogrel,
but there is little information about the use of strategies to
select patients who might do better with prasugrel. There is
not yet experience with the use of prasugrel in routine
community practice. As a result, the writing group believes
that there is some uncertainty regarding the net benefit and
risks of 1 drug over another for a given patient. Consider-
ations of efficacy in the prevention of thrombosis and risk of
an adverse effect related to bleeding, as well as experience
with a given medication, may best guide decisions about the
choice of thienopyridine for individual patients.
3.2. Proton Pump Inhibitors and Dual-Antiplatelet
Therapy for ACS
Proton pump inhibitors (PPIs) are often prescribed prophy-
lactically when clopidogrel is started, to prevent gastrointes-
tinal complications such as ulceration and related bleeding59
due to dual-antiplatelet therapy, in particular ASA and
clopidogrel.32 Coupled with concern about the gastrointesti-
nal precautions, there has been increased emphasis on the
prevention of premature discontinuation of dual-antiplatelet
therapy, particularly in patients who have received a stent
(BMS or DES), for whom 12 months of antiplatelet therapy is
recommended.28 PPI medications* have been found to inter-
fere with the metabolism of clopidogrel.34
Although there are studies that show a pharmacodynamic
interaction on ex vivo platelet function testing, to date there are
no convincing randomized clinical trial data for an important
clinical drug–drug interaction. Retrospective claims-based re-
ports suggesting clinical harm, some detailed below, may be
confounded by different baseline characteristics and lack of
compliance data. There have been retrospective reports of
adverse cardiovascular outcomes (eg, readmission for ACS)
when the antiplatelet regimen of clopidogrel and ASA is
accompanied by PPIs, assessed as a group, compared with the
use of this regimen without a PPI.32–34,60 In a retrospective
cohort study from the Veterans Affairs’ medical records and
pharmacy database, concomitant clopidogrel and PPI therapy
(with omeprazole, rabeprazole, lansoprazole, or pantoprazole) at
any time point during follow-up of 8205 patients discharged for
ACS was associated with an increased risk of death or rehospi-
talization for ACS.32 Other post hoc study analyses50,61 and a
retrospective data analysis from the NHLBI Dynamic Registry62
in which PPIs were assessed as a class in combination with a
clopidogrel and an ASA regimen have not found an effect of PPI
therapy on the clinical effect of clopidogrel in ACS patients,
after ACS, or in a general post-PCI population,
respectively.50,61,62
Some studies have suggested that adverse cardiovascular
outcomes with the combination of clopidogrel and a PPI are
*PPIs include omeprazole, lansoprazole, pantoprazole, rabeprazole, and es-
omeprazole (which are all available by prescription). Omeprazole is also sold
over the counter for frequent heartburn.66
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explained by the individual PPI, in particular the use of a PPI
that inhibits CYP450 2C19, which includes omeprazole,
lansoprazole, and rabeprazole. The PPI omeprazole notably
has been reported to significantly decrease the inhibitory
effect of clopidogrel on platelet aggregation.63,64 One study
reported that the PPI pantoprazole was not associated with
recurrent MI among patients receiving clopidogrel, possibly
because of its lack of inhibition of CYP450 2C19.33
Other studies have examined the thienopyridine agent
prescribed with the PPI. One open-label drug study evaluated
the effects of the PPI lansoprazole on the pharmacokinetics
and pharmacodynamics of prasugrel and clopidogrel in
healthy subjects given single doses of prasugrel (60 mg) and
clopidogrel (300 mg) with and without concurrent lansopra-
zole 30 mg per day. The data suggest that inhibition of
platelet aggregation was reduced in patients who took the
combination of clopidogrel and lansoprazole, whereas it was
unaffected after a prasugrel dose.56
Another study35 assessed the association of PPIs with the
pharmacodynamics and clinical efficacy of clopidogrel and
prasugrel, based on populations from 2 randomized trials, the
PRINCIPLE (Prasugrel In Comparison to Clopidogrel for
Inhibition of Platelet Activation and Aggregation) TIMI-44
trial65 and the TRITON-TIMI 38 trial.27 The findings indi-
cated that first, PPI treatment attenuated the pharmacody-
namic effects of clopidpgrel and, to a lesser extent, those of
prasugrel. Secondly, PPI treatment did not affect the clinical
outcome of patients given clopidogrel or prasugrel. This
finding was true for all PPIs that were studied, including
omeprazole and pantoprazole.
The FDA communication concerning an ongoing safety
review of clopidogrel bisulfate66 advises that healthcare
providers avoid the use of clopidogrel in patients with
impaired CYP2C19 function due to known genetic varia-
tion or due to drugs that inhibit CYP2C19 activity. The
FDA notes that there is no evidence that other drugs that
reduce stomach acid, such as H2 blockers or antacids,
interfere with the antiplatelet activity of clopidogrel.
Further research with thienopyridines and PPI combina-
tions, particularly drugs that are not dependent on CYP450
2C19, is needed. Consideration may be given to the use of H2
antagonists as an alternative to PPIs in the setting of dual-
antiplatelet therapy, although they cannot be relied on to
protect as well as PPIs, and there are few data about their use
with ASA.59 The FAMOUS (Famotidine for the Prevention of
Peptic Ulcers in Users of Low-Dose Aspirin) trial, a phase II,
double-blind, randomized, placebo-controlled trial, found that
among patients with a history of coronary heart disease,
diabetes mellitus, or cerebrovascular disease who were taking
low-dose ASA, 12 weeks of famotidine 20 mg twice daily
(n204) compared with placebo twice daily (n200) was
beneficial in reducing the incidence of peptic ulcer or
esophagitis during follow-up endoscopy at 12 weeks. The rate
of occurrence of a gastric ulcer at endoscopy at 12 weeks was
3.4% in the famotidine group versus 15% in the placebo
group (P0.0002), duodenal ulcer occurred in 0.5% versus
8.5% (P0.0045), and erosive esophagitis was seen in 4.4%
versus 19% (P0.0001), respectively. Of note, in the famo-
tidine group, clopidogrel use was 19% and dipyridamole use
was 6%.67 The writing committee concluded that additional
data, notably randomized controlled clinical trial data that
have been peer reviewed and published, are needed before an
official recommendation can be made about the use of dual
antiplatelet therapy with PPIs in the setting of ACS.
4. Recommendations for the Use of
Parenteral Anticoagulants
(See Table 4 and Appendix 4.)
4.1. Parenteral Anticoagulants
Parenteral anticoagulants include intravenous UFH, bivaliru-
din, enoxaparin, and fondaparinux. Bivalirudin was briefly
cited in the 2007 STEMI focused update. The HORIZONS-
AMI trial, which was reported subsequently, was a prospec-
tive, open-label, randomized, multicenter, international trial
that included 3602 patients with STEMI undergoing primary
PCI. Patients were randomized to treatment with UFH plus a
GP IIb/IIIa receptor antagonist or to bivalirudin alone (with
provisional abciximab or double-bolus eptifibatide). The
primary efficacy end point was a composite of net adverse
clinical events, including major bleeding plus MACE, a
composite of cardiovascular death, reinfarction, TVR for
ischemia, and stroke within 30 days. Bivalirudin alone
resulted in a lower incidence of net adverse clinical events at
30 days (9.2% versus 12.1%; RR 0.76; 95% CI 0.63 to 0.92;
P0.005; NNT34) and at 1 year (15.7% versus 18.3%, HR
0.84; 95% CI 0.71 to 0.98; P0.3).9 The difference was
driven by a significant decrease in major bleeding complica-
tions with bivalirudin at 30 days (4.9% versus 8.3%,
P0.001; number needed to harm33) and 1 year (5.8%
versus 9.2%, P0.001). There was a statistically significant
1% increase in stent thrombosis (n17) within the first 24
hours with bivalirudin but no subsequent difference (1.3%
versus 0.3%, P0.001). More deaths at 30 days occurred
after major bleeding (n26) than after reinfarction (n10) or
definite stent thrombosis (n5).9 Treatment with bivalirudin
resulted in significantly lower 30-day rates of death due to
cardiac causes (1.8% versus 2.9%; RR 0.62; 95% CI 0.40 to
0.95; P0.03) and death due to all causes (2.1% versus 3.1%;
RR 0.66; 95% CI 0.44 to 1.00; P0.047 compared with UFH
plus GP IIb/IIIa inhibitors). At 1 year, MACE rates were
identical, but there was a decrease in all-cause mortality with
bivalirudin (3.4% versus 4.8%, P0.03).68
Concerns about the trial include its open-label design and
the administration of UFH before randomization in 66% of
patients in the bivalirudin arm and 76% of patients in the
UFH plus GP IIb/IIIa receptor antagonist arm. Only 615
patients received bivalirudin monotherapy, and only 60% of
patients in the trial received a 600-mg clopidogrel loading
dose. Major bleeding as defined in the publication included
hematomas of 5 cm, intracranial hemorrhage, and bleeding
that required surgery. Additionally, the study put forth a
composite primary end point that combined efficacy and
safety. Although there were no statistically significant inter-
actions at 30 days between the treatment assignment and
preprocedural UFH use or clopidogrel loading dose with
respect to MACE or major bleeding, the occurrence of an
increase in early stent thrombosis with bivalirudin and the
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excess bleeding with UFH and GP IIb/IIIa inhibitors may be
related to the degree of platelet inhibition and antithrombin
activity associated with these treatment doses.
A preliminary report suggested that the use of bivalirudin
alone (P0.005) and a lower loading dose of clopidogrel
(300 versus 600 mg; P0.01) were independent predictors of
acute and subacute stent thrombosis rates, respectively.69
Probability values for secondary end points may not have
been adjusted for multiple looks.
Therefore, the writing group now considers bivalirudin
useful for primary PCI in STEMI whether or not the patient
received pretreatment with UFH. The risk of acute stent
thrombosis associated with bivalirudin appeared to be miti-
gated by the prior use of UFH and the risk of subacute stent
thrombosis by the use of a 600-mg loading dose of clopi-
dogrel. These data should be confirmed by prospective
studies.
5. Recommendations for Triage and Transfer
for PCI
(See Table 5 and Appendix 5.)
5.1. Triage and Transfer for PCI
5.1.1. STEMI Patients Who Are Candidates for Reperfusion
The 2007 STEMI Focused Update describes several strate-
gies for reperfusion, among them facilitated PCI and rescue
PCI.4 These terms are no longer used for the recommenda-
tions in this update so that the contemporary therapeutic
choices that lead to reperfusion as part of the treatment of
patients presenting with STEMI can be described without
these potentially misleading labels.
A brief review of facilitated PCI, however, is needed. This
strategy involves full- or half-dose fibrinolytic therapy with
or without a GP IIb/IIIa receptor antagonist, followed by
immediate PCI. Two studies addressed this issue: ASSENT-4
PCI (Assessment of the Safety and Efficacy of a New
Treatment Strategy With Percutaneous Coronary Interven-
tion),70 which was described in detail in the 2007 PCI and
STEMI focused updates, and FINESSE,71 which was a
randomized, double-blind clinical trial of 2452 patients ran-
domized within 6 hours of symptom onset to receive reduced-
dose reteplase plus abciximab followed by PCI (combination-
facilitated PCI), abciximab alone followed by PCI
(abciximab-facilitated PCI), or placebo (primary PCI).
ASSENT-4 patients treated with fibrinolytic therapy
before PCI had increased rates of adverse outcomes,
including in-hospital death (6% versus 3%). The investi-
gators theorized that suboptimal antithrombotic therapy
(ie, the lack of a heparin infusion after bolus administra-
tion, no upfront loading dose of clopidogrel, and prohibi-
tion of IIb/IIIa use except for bailout) and a short time
Table 4. Recommendations for the Use of Parenteral Anticoagulants
STEMI Recommendations PCI Recommendations
2009 Joint STEMI/PCI Focused Update
Recommendations Comments
2007 STEMI Update, Section 8 2007 PCI Guideline Update, Table 13
Class I
2. For patients undergoing PCI after having
received an anticoagulant regimen, the
following dosing recommendations should
be followed:
a. For prior treatment with UFH,
administer additional boluses of UFH
as needed to support the procedure,
taking into account whether GP IIb/IIIa
receptor antagonists have been
administered. (Level of Evidence: C)
Bivalirudin may also be used in
patients treated previously with UFH.
(Level of Evidence: C)
b. For prior treatment with enoxaparin, if
the last subcutaneous dose was
administered within the prior 8 hours,
no additional enoxaparin should be
given; if the last subcutaneous dose
was administered at least 8 to 12
hours earlier, an intravenous dose of
0.3 mg per kg of enoxaparin should
be given. (Level of Evidence: B)
c. For prior treatment with fondaparinux,
administer additional intravenous
treatment with an anticoagulant
possessing anti-IIa activity taking into
account whether GP IIb/IIIa receptor
antagonists have been administered.
(Level of Evidence: C)
1. For patients undergoing PCI after having received
an anticoagulant regimen, the following dosing
recommendations should be followed:
a. For prior treatment with UFH, administer
additional boluses of UFH as needed to support
the procedure, taking into account whether GP
IIb/IIIa receptor antagonists have been
administered. (Level of Evidence: C) Bivalirudin
may also be used in patients treated previously
with UFH. (Level of Evidence: C)
b. For prior treatment with enoxaparin, if the last
subcutaneous dose was administered at least 8
to 12 hours earlier, an IV (intravenous) dose of
0.3 mg/kg of enoxaparin should be given; if the
last subcutaneous dose was administered within
the prior 8 hours, no additional enoxaparin
should be given. (Level of Evidence: B)
c. For prior treatment with fondaparinux, administer
additional intravenous treatment with an
anticoagulant possessing anti-IIa activity, taking
into account whether GP IIb/IIIa receptor
antagonists have been administered. (Level of
Evidence: C)
1. For patients proceeding to primary
PCI who have been treated with
ASA and a thienopyridine,
recommended supportive
anticoagulant regimens include the
following:
a. For prior treatment with UFH,
additional boluses of UFH should
be administered as needed to
maintain therapeutic activated
clotting time levels, taking into
account whether GP IIb/IIIa
receptor antagonists have been
administered. (Level of
Evidence: C)
b. Bivalirudin is useful as a
supportive measure for primary
PCI with or without prior treatment
with UFH.9 (Level of
Evidence: B)
Modified recommendation. (Bivalirudin
was added as an acceptable
anticoagulant for primary PCI; text
about UFH was modified to
mention activated clotting time
levels. Information on enoxaparin
and fondaparinux was not
imported because
recommendations concerning
these drugs were unchanged.)
Class IIa
1. In STEMI patients undergoing PCI
who are at high risk of bleeding,
bivalirudin anticoagulation is
reasonable.9 (Level of Evidence: B)
New recommendation
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from fibrinolytic therapy to PCI contributed in part to the
adverse clinical outcomes.
FINESSE8 showed that neither PCI preceded by abciximab
and reteplase nor PCI preceded by abciximab alone was
superior to abciximab used at the time of PCI among patients
presenting within 4 hours of medical contact. Neither the
primary end point (a composite of death due to all causes,
ventricular function more than 48 hours after randomization,
cardiogenic shock, and congestive heart failure during the
first 90 days after randomization) nor mortality was signifi-
cantly different among the groups. Although the study was
terminated early because of recruitment challenges, there was
less than a 2% chance that the primary treatment group
difference would be significant if the trial had been allowed
to continue to its planned completion.
The indications for rescue PCI have been defined by a
combination of clinical and electrocardiographic clues that an
infarct artery has not reperfused. These are relief of pain and
resolution of ST-segment elevation. Although complete relief
of pain and complete resolution of ST elevation are reason-
ably predictive of reperfusion after fibrinolytic therapy, this is
not a common occurrence. In the 2007 STEMI Focused
Update, the writing committee held that at 90 minutes after
initiation of fibrinolytic therapy, if there was less than 50%
ST-segment resolution in the lead that showed the greatest
degree of ST elevation at presentation, then fibrinolytic
Table 5. Recommendations for Triage and Transfer for PCI
2004/2005/2007 Recommendations 2009 Joint STEMI/PCI Focused Update Recommendations Comments
Class I
1. Each community should develop a STEMI system of care that follows
standards at least as stringent as those developed for the AHA’s
national initiative, Mission: Lifeline, to include the following:
● ongoing multidisciplinary team meetings that include emergency
medical services, non–PCI-capable hospitals/STEMI referral
centers, and PCI-capable hospitals/STEMI receiving centers to
evaluate outcomes and quality improvement data;
● a process for prehospital identification and activation;
● destination protocols for STEMI receiving centers;
● transfer protocols for patients who arrive at STEMI referral centers
who are primary PCI candidates, are ineligible for fibrinolytic
drugs, and/or are in cardiogenic shock. (Level of Evidence: C)
New recommendation
Class IIa
1. It is reasonable for high-risk* patients who receive fibrinolytic
therapy as primary reperfusion therapy at a non–PCI-capable facility
to be transferred as soon as possible to a PCI-capable facility where
PCI can be performed either when needed or as a pharmacoinvasive
strategy. Consideration should be given to initiating a preparatory
antithrombotic (anticoagulant plus antiplatelet) regimen before and
during patient transfer to the catheterization laboratory.14,15 (Level of
Evidence: B)
New recommendation
(see Appendix 5)
Class IIb
(From 2007 STEMI Update, Section 5)
1. Facilitated PCI using regimens other than full-dose
fibrinolytic therapy might be considered as a
reperfusion strategy when all of the following are
present: a. Patients are at high risk, b. PCI is not
immediately available within 90 minutes, and c.
Bleeding risk is low (younger age, absence of
poorly controlled hypertension, normal body
weight). (Level of Evidence: C)
1. Patients who are not at high risk who receive fibrinolytic therapy as
primary reperfusion therapy at a non–PCI-capable facility may be
considered for transfer as soon as possible to a PCI-capable facility
where PCI can be performed either when needed or as a
pharmacoinvasive strategy. Consideration should be given to
initiating a preparatory antithrombotic (anticoagulant plus antiplatelet)
regimen before and during patient transfer to the catheterization
laboratory. (Level of Evidence: C)
Modified
recommendation
(changed text).
(From 2007 STEMI Update, Section 6)
1. A strategy of coronary angiography with intent to
perform PCI in the absence of 1 or more of the
above Class I or IIa indications might be
reasonable in moderate- and high-risk patients,
but its benefits and risks are not well established.
The benefits of rescue PCI are greater the earlier
it is initiated after the onset of ischemic
discomfort. (Level of Evidence: C)
Deleted recommendation
(covered by new
recommendations,
above)
*High risk was defined in the CARESS-in-AMI15 study as STEMI patients with 1 high-risk feature (extensive ST-segment elevation, new-onset left bundle-branch
block, previous MI, Killip class2, or left ventricular ejection fraction35% for inferior MIs; anterior MI alone with2 mm of ST elevation in2 leads also qualified
the patient as being at high risk). It was defined in TRANSFER-AMI14 as2 mm of ST-segment elevation in 2 anterior leads or ST elevation of at least 1 mm in inferior
leads with at least 1 of the following: systolic blood pressure100 mm Hg, heart rate100 bpm, Killip class II to III,2 mm of ST-segment depression in the anterior
leads, or 1 mm of ST elevation in right-sided lead V4 indicative of right ventricular involvement.
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therapy had likely failed to reperfuse the patient.4 If the
judgment was made that fibrinolytic therapy had not resulted
in reperfusion after 90 minutes, then PCI performed at that
time was labeled rescue PCI.
The 2007 STEMI Focused Update4 recommended rescue
PCI in the following cases: Fibrinolytic-treated STEMI pa-
tients meeting high-risk criteria (ie, cardiogenic shock [less
than 75 years of age, Class I; 75 years of age or older, Class
IIa]); hemodynamic or electrical instability; persistent ische-
mic symptoms; and for certain moderate- and high-risk
patients who did not strictly meet the above criteria (Class
IIb). These recommendations were based on results of the
REACT (Rescue Angioplasty Versus Conservative Treat-
ment of Repeat Thrombolysis) trial74 which showed a clear
benefit of rescue PCI (over repeated doses of fibrinolytics or
medical management) in moderate- to high-risk patients with
failed reperfusion, as well as a meta-analysis of 8 rescue PCI
trials (including REACT).73–76 The 2007 focused update
acknowledged that the expected benefits of rescue PCI are
greater the earlier it is initiated after the onset of ischemic
symptoms.
Two new trials have helped inform this update: The
CARESS-in-AMI trial and the TRANSFER-AMI trial.
CARESS-in-AMI15 studied 600 STEMI patients 75 years of
age or younger with at least 1 high-risk feature (extensive
ST-segment elevation, new-onset left bundle-branch block,
previous MI, Killip class greater than 2, or left ventricular
ejection fraction 35% or less) who were treated initially at
non-PCI hospitals with half-dose reteplase, abciximab, hep-
arin, and ASA within 12 hours of symptom onset.3 All
patients were randomized to immediate transfer for PCI or to
standard treatment with transfer for rescue PCI if needed. PCI
was performed in 85.6% of patients in the immediate PCI
group, and rescue PCI was performed in 30.3% of the
standard treatment/transfer for rescue PCI group. There was a
shorter median time from fibrinolytic therapy to transfer to a
PCI-capable center in the immediate versus the rescue PCI
group (110 versus 180 minutes, P0.0001). Antiplatelet
therapy with ASA and clopidogrel was used less frequently in
the standard care/rescue arm than in the early intervention
group. The primary outcome (composite of all-cause mortal-
ity, reinfarction, and refractory myocardial ischemia within
30 days of randomization) occurred significantly less often
(4.4% versus 10.7%, P0.004) in the immediate PCI group
than in the standard care/rescue PCI group (NNT17). There
were no significant differences in the rates of major bleeding
at 30 days (3.4% versus 2.3%, P0.47) or stroke (0.7%
versus 1.3%, P0.50) between groups. These results suggest
that high-risk STEMI patients treated at non-PCI hospitals
with a preparatory pharmacological strategy of half-dose
fibrinolytic therapy, abciximab, heparin, and ASA have
improved outcomes when transferred immediately to a PCI
facility rather than when medical therapy is continued with
transfer for rescue PCI only if there is evidence of failed
reperfusion.
The TRANSFER-AMI study14 further tested the pharma-
coinvasive strategy concept in high-risk STEMI patients.
Accordingly, 1059 patients who presented to a non–PCI-
capable hospital within 12 hours of symptom onset of STEMI
who had at least 1 high-risk feature (greater than or equal to
2 mm of ST-segment elevation in 2 anterior leads, systolic
blood pressure less than 100 mm Hg, heart rate higher than
100 bpm, Killip class II to III, 2 mm or more of ST-segment
depression in the anterior leads, or 1 mm or more of ST
elevation in right-sided lead V4 indicative of right ventricular
involvement for inferior MIs; anterior MI alone with 2 mm or
more of ST-segment elevation in 2 or more leads also
qualified) and who were treated with fibrinolytic therapy
were randomized to a pharmacoinvasive strategy (immediate
transfer for PCI within 6 hours of fibrinolytic therapy) or to
standard treatment after fibrinolytic therapy, which included
rescue PCI as required for ongoing chest pain and less than
50% resolution of ST elevation at 60 to 90 minutes or
hemodynamic instability. Standard-treatment patients who
did not require rescue PCI remained at the initial hospital for
at least 24 hours, and coronary angiography within the first 2
weeks was encouraged.
All patients received standard-dose tenecteplase, ASA, and
either UFH or enoxaparin. Clopidogrel loading (300 mg for
patients 75 years of age or younger and 75 mg for those older
than 75 years of age) was strongly encouraged in all study
patients. GP IIb/IIIa receptor antagonists were administered
at the PCI-capable hospitals according to standard practice at
the institution. The primary end point of the trial was the
30-day composite of the first occurrence of death, reinfarc-
tion, recurrent ischemia, new or worsening heart failure, and
cardiogenic shock.
The median time to administration of tenecteplase from
onset of symptoms was approximately 2 hours in both groups,
whereas the median time from tenecteplase administration to
catheterization was 2.8 hours in the pharmacoinvasive group
and 32.5 hours in the standard-treatment group. Coronary
angiography was performed in 98.5% versus 88.7% and PCI
in 84.9% versus 67.4% of the pharmacoinvasive and
standard-treatment groups, respectively.
The primary end point of the trial occurred in 11.0% of the
pharmacoinvasive group compared with 17.2% of the
standard-treatment group (RR 0.64; 95% CI 0.47 to 0.84;
P0.004). Importantly, the incidence of TIMI major and
minor bleeding and GUSTO (Global Use of Strategies to
Open Occluded Coronary Arteries)77 moderate and severe
bleeding was not different between groups, although there
was a higher incidence of GUSTO mild bleeding in the
pharmacoinvasive group (13.0% compared with 9.0% in the
standard-treatment group, P0.036). The authors concluded
that after treatment with fibrinolytic therapy in STEMI
patients presenting to hospitals without PCI capability, trans-
fer to a PCI center to undergo coronary angiography and PCI
should be initiated immediately without waiting to determine
whether reperfusion has occurred. These results lend further
support to the routine, early transfer of high-risk, fibrinolytic-
treated patients to a PCI center for early PCI supported by
contemporary antiplatelet and antithrombotic therapy.
On the basis of this evidence, a pathway has been sug-
gested for the care of STEMI patients that has been divided
into those patients presenting to a PCI-capable facility and
those presenting to a non–PCI-capable facility (Appendix 5).
Those seen at a PCI-capable facility should be moved
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expeditiously to the catheterization laboratory, with appropri-
ate antithrombotic therapy for catheterization and PCI if
appropriate. There has been discussion about whether the
recommended door-to-balloon time (or first medical contact–
to-balloon time) should be greater than 90 minutes, with the
recognition that in certain patients, the mortality advantage of
primary PCI compared with fibrinolytic therapy is maintained
with more prolonged door-to-balloon times.78 However, the
writing groups continue to believe that the focus should be on
developing systems of care to increase the number of patients
with timely access to primary PCI rather than extending the
acceptable window for door-to-balloon time.79 Moreover, in a
study of 43 801 patients with STEMI undergoing primary
PCI within the National Cardiovascular Data Registry, any
delay in time to reperfusion after arrival at the hospital was
associated with a higher adjusted risk of in-hospital mortality
in a continuous, nonlinear fashion (30 minutes3.0%, 60
minutes3.5%, 90 minutes4.3%, 120 minutes5.6%, 150
minutes7.0%, and 180 minutes8.4%; P0.001).80 Rather
than accepting a 90-minute door-to-balloon benchmark for
primary PCI, these data suggest an as-soon-as-possible
standard.
Those patients presenting to a non–PCI-capable facility
should be triaged to fibrinolytic therapy or immediate transfer
for PCI. This decision will depend on multiple clinical
observations that allow judgment of the mortality risk of the
STEMI, the risk of fibrinolytic therapy, the duration of the
symptoms when first seen, and the time required for transport
to a PCI-capable facility.3 If primary PCI is chosen, the
patient will be transferred for PCI. If fibrinolytic therapy is
chosen, the patient will receive the agent(s), and a judgment
as to whether the patient is high risk or not will be made. If
high risk, the patient should receive appropriate antithrom-
botic therapy and be moved immediately to a PCI-capable
facility for diagnostic catheterization and consideration of
PCI. If not high risk, the patient may be moved to a
PCI-capable facility after receiving antithrombotic therapy or
may be observed in the initial facility.
Patients best suited for transfer for PCI are those STEMI
patients who present with high-risk features, those with high
bleeding risk from fibrinolytic therapy, and patients pres-
enting late, that is, more than 4 hours after onset of symp-
toms. The decision to transfer is a judgment made after
consideration of the time required for transport and the
capabilities of the receiving hospital.2,5 Patients best suited
for fibrinolytic therapy are those who present early after
symptom onset with low bleeding risk. After fibrinolytic
therapy, if the patient is not at high risk, transfer to a
PCI-capable facility may be considered, especially if symp-
toms persist and failure to reperfuse is suspected.
The duration of symptoms should continue to serve as a
modulating factor in selecting a reperfusion strategy for
STEMI patients. Although patients at high risk (eg, those
with congestive heart failure, shock, and contraindications to
fibrinolytic therapy) are best served with timely PCI, “inor-
dinate delays between the time from symptom onset and
effective reperfusion with PCI may prove deleterious, espe-
cially among the majority of STEMI patients at relatively low
risk” (p 1299).81 Accordingly, each community and each
facility in that community should have an agreed-upon plan
for how STEMI patients are to be treated. This includes
which hospitals should receive STEMI patients from emer-
gency medical services units capable of obtaining diagnostic
ECGs, management at the initial receiving hospital, and
written criteria and agreements for expeditious transfer of
patients from non–PCI-capable to PCI-capable facilities.82
The development of regional systems of STEMI care is a
matter of utmost importance.83,84 This includes encouraging
the participation of key stakeholders in collaborative efforts
to evaluate care using standardized performance and quality
improvement measures, such as those endorsed by the ACC
and the AHA for ACS.85 Standardized quality-of-care data
registries designed to track and measure outcomes, compli-
cations, and adherence to evidence-based processes of care
for ACS are also critical: programs such as the National
Cardiovascular Data Registry ACTION Registry, the AHA’s
“Get With The Guidelines” quality improvement program,
and those performance-measurement systems required by the
Joint Commission and the Centers for Medicare and Medic-
aid Services.86–89 More recently, the AHA has promoted its
“Mission: Lifeline” initiative, which was developed to en-
courage closer cooperation and trust among prehospital emer-
gency services, and cardiac care professionals.90 The evalu-
ation of STEMI care delivery across traditional care-delivery
boundaries with these tools and other resources is imperative
to identify systems problems and to enable the application of
modern quality improvement methods, such as Six Sigma, to
make necessary improvements.70,91–93
6. Recommendations for Intensive Glucose Control
in STEMI
(See Table 6.)
6.1. Intensive Glucose Control
As detailed in the 2004 STEMI guideline and the 2007
UA/NSTEMI guideline revision, randomized trial evidence
supported the use of insulin infusion to control hyperglyce-
mia.3,97 A recently published randomized clinical trial of
intensive versus conventional glucose control in critically ill
patients raised uncertainty regarding the optimal level to
target when achieving glucose control. NICE-SUGAR, a
large, international randomized trial (n6104) of adults
admitted to the intensive care unit with either medical or
surgical conditions, compared intensive glucose control (tar-
get glucose range 81 to 108 mg/dL) with conventional
glucose control (to achieve a glucose level less than 180
mg/dL, with reduction and discontinuation of insulin if the
blood glucose level dropped below 144 mg/dL).16 Time-
weighted glucose levels achieved were 11518 mg/dL in the
intensive glucose control group versus 14423 mg/dL in the
conventional glucose control group. The risk of death was
increased at 90 days in the intensive glucose control group by
2.6% (27.5% versus 24.9%; odds ratio 1.14; 95% CI 1.02 to
1.08; P0.02; number needed to harm38). The result
remained the same after adjustment for potential confounders.
There were significantly more episodes of treatment-related
hypoglycemia in the intensely managed group (6.8% versus
0.5%, P0.001), although the contribution of hypoglycemia
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to excess mortality is uncertain.94,98 Overall, the hospital
course and proximate causes of death were similar in the 2
groups. Excess deaths in the intensive-control group were
predominantly due to cardiovascular causes (absolute differ-
ence 5.8%; P0.02). More patients in the intensive-control
group than in the conventional-control group were treated
with corticosteroids.
Because NICE-SUGAR enrolled critically ill medical and
surgical patients, the degree to which its results can be
extrapolated to the management of patients with STEMI is
unclear. Although recent data from a small, mechanistic
clinical trial28,29,98 suggest that glucose control may reduce
inflammation and improve left ventricular ejection fraction in
patients with acute myocardial infarction (AMI), whether it
will improve patient outcomes remains uncertain.
A consensus statement by the American Association of
Clinical Endocrinologists and the American Diabetes Asso-
ciation99 summarized that “although hyperglycemia is asso-
ciated with adverse outcomes after AMI, reduction of glyce-
mia per se, and not necessarily the use of insulin, is associated
with improved outcomes. It remains unclear, however,
whether hyperglycemia is a marker of underlying health
status or is a mediator of complications after AMI. Noniatro-
genic hypoglycemia has also been associated with adverse
outcomes and is a predictor of higher mortality” (p 1120).99
There is a clear need for a well-designed, definitive random-
ized trial of target-driven glucose control in STEMI that has
meaningful clinical end points to determine glucose treatment
thresholds and glucose targets. Until such a trial is completed,
and based on the balance of current evidence,99–101 the writing
group concluded that it was prudent to change the recommen-
dation for the use of insulin to control blood glucose in STEMI
from a Class I to a Class IIa recommendation (Level of Evidence:
B) and to recommend treatment for hyperglycemia greater than
180 mg/dL while avoiding hypoglycemia.
7. Recommendation for Thrombus Aspiration
During PCI for STEMI
(See Table 7.)
7.1. Thrombus Aspiration
Since the publication of the last STEMI and PCI focused
updates, 2 new trials of manual thrombus aspiration have been
published. TAPAS was a single-center, unblinded, randomized
clinical trial that compared 2 catheter-based reperfusion strate-
gies in 1071 patients with STEMI.17,102 Before coronary angiog-
raphy, patients were randomized to manual thrombus aspiration
before PCI (55.1% by direct stenting, 28.6% by balloon angio-
plasty followed by stenting, 10.1% by PCI without thrombus
aspiration) or conventional PCI with balloon angioplasty fol-
lowed by stenting. BMS were implanted in 92% of PCI
procedures. All patients were treated with ASA, 600 mg of
clopidogrel, UFH, and abciximab unless contraindicated. TIMI
myocardial blush grade 0 or 1 occurred in 17.1% of patients with
thrombus aspiration and 26.3% of those with conventional PCI
(P0.001). Complete resolution of ST-segment elevation oc-
curred in 56.6% and 44.2%, respectively (P0.001). Death,
reinfarction, and TVR rates at 30 days were not significantly
different (6.8% versus 9.4%).17 However, at 1 year, rates of
cardiac death (3.6% versus 6.7%, P0.02) and cardiac death or
nonfatal reinfarction (5.6% versus 9.9%, P0.009) were lower
with thrombus aspiration. Low myocardial blush grade and
incomplete ST-segment resolution were associated with clinical
events.102
EXPIRA was a smaller (n175) randomized clinical trial
that also compared thrombus aspiration with conventional
PCI, but only in patients with TIMI flow 0/1.18 TIMI
myocardial blush grade of 2 or more (88% versus 60%,
Table 6. Recommendations for Intensive Glucose Control in STEMI
2004/2005/2007 Recommendations: 2004 STEMI
Guidelines 2009 Joint STEMI/PCI Focused Update Recommendations Comments
Class I
1. An insulin infusion to normalize blood glucose
is recommended for patients with STEMI and
complicated courses. (Level of Evidence: B)
Recommendation is no longer current.
See 2009 Class IIa
recommendation #1.
Class IIa
1. It is reasonable to use an insulin-based regimen to achieve
and maintain glucose levels less than 180 mg/dL while
avoiding hypoglycemia* for patients with STEMI with either
a complicated or uncomplicated course.16,94–96 (Level of
Evidence: B)
New recommendation
1. During the acute phase (first 24 to 48 hours)
of the management of STEMI in patients with
hyperglycemia, it is reasonable to administer
an insulin infusion to normalize blood glucose
even in patients with an uncomplicated
course. (Level of Evidence: B)
Recommendation is no longer current.
See 2009 Class IIa
recommendation #1.
*There is uncertainty about the ideal target range for glucose necessary to achieve an optimal risk-benefit ratio.
Table 7. Recommendation for Thrombus Aspiration During PCI
for STEMI
2009 Joint STEMI/PCI Focused Update
Recommendation Comments
Class IIa
1. Aspiration thrombectomy is reasonable for
patients undergoing primary PCI.17,18,102
(Level of Evidence: B)
New recommendation
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P0.001) and 90-minute ST-segment resolution greater than
70% (64% versus 39%, P0.001) occurred more frequently
in the thrombus aspiration group. Infarct size measured by
contrast-enhanced magnetic resonance imaging in 75 patients
at 3 months was significantly reduced only in the thrombus
aspiration group.
Both of these trials, as well as a meta-analysis by Bavry et
al103 and a large pooled analysis of randomized trials,104
support the use of aspiration thrombectomy for STEMI. In
developing a recommendation for the role of routine aspira-
tion thrombectomy, however, it is noteworthy that TAPAS
was a study of routine thrombus aspiration versus no throm-
bus aspiration rather than a study of routine thrombus
aspiration versus selective thrombus aspiration. It is not
known whether a strategy of selective thrombus aspiration in
patients with a large thrombus burden might be superior to no
thrombus aspiration or equivalent to routine thrombus aspi-
ration. Clinically, it is reasonable to assume that this strategy
can be useful in STEMI patients with short ischemic times
and large thrombus burden. It may not be helpful in STEMI
patients with long ischemic times, side branches with small
infarct territories, or lesions with low thrombus burden.
8. Recommendations for the Use of Stents
in STEMI
(See Table 8.)
8.1. Stent Selection for STEMI
Primary PCI is generally the preferred reperfusion strategy
for patients with STEMI.110 Compared with balloon angio-
plasty, routine BMS implantation during primary PCI de-
creases risk for TVR and possibly reduces MI rates but does
not reduce mortality rates.111,112
Two-year data from the Massachusetts registry113 from
1221 propensity score–matched pairs of DES and BMS
patients demonstrated a reduction in mortality and TVR rates
with DES in primary PCI, and an analysis from the New York
State registry114 found a reduction in mortality rates but not
TVR rates with DES. These reports were limited to patients
treated before 2005, so they represent the earliest experience
with DES, in which selection bias may have influenced stent
choice and off-label use may have been pursued more
cautiously. Additionally, duration of clopidogrel therapy was
longer in the DES group.
More recently, several relatively small randomized clinical
trials have shown an inconsistent efficacy for DES over BMS
in primary PCI. Three meta-analyses of these trials have
concluded that there were no differences in death, MI, or stent
thrombosis rates, but TVR rates were decreased with
DES.115–117 Variably included were 12 studies that differed in
trial design, inclusion criteria, end-point definitions, stent
types, duration of clopidogrel treatment, and type of
follow-up (angiographic versus clinical). They were limited
by sample size and duration of follow-up and by usually
requiring angiographic documentation of stent thrombosis,
which may have underestimated its true incidence.
The HORIZONS-AMI trial randomized, in a 3-to-1 ratio,
3006 patients to DES or BMS.9,68,105 There was no differ-
ence in the 12-month composite safety end point of death,
reinfarction, stroke, or stent thrombosis. The rates of
ischemia-driven TVR and target-lesion revascularization
were significantly lower in the DES group (5.8% versus
8.7% and 4.5% versus 7.5%, respectively; NNT33 at 1
year), as was the 13-month binary restenosis rate (10.0%
versus 22.9%).
In summary, there appears to be no difference between
BMS and DES in mortality or MI rates and no difference in
stent thrombosis risk. The major advantage of DES over BMS
is a small reduction in TVR rates. Given cost considerations,
it could be argued that selective use of DES to prevent
restenosis and TVR in high-risk patients (ie, patients with
diabetes) and in high-risk lesions (longer and smaller-
diameter stents) could be recommended,118 as it has been for
elective PCI. The greatest challenge in selecting patients for
DES implantation, however, is determining in an emergency
situation whether the patient is a candidate for prolonged
thienopyridine therapy. As with elective procedures, DES
should be avoided in the presence of financial barriers to
continuing prolonged dual-antiplatelet therapy, social barriers
that may limit patient compliance, or medical issues that
involve bleeding risks or the need for invasive or surgical
procedures in the following year that would interrupt anti-
platelet therapy.
Table 8. Recommendations for the Use of Stents in STEMI
2004/2005/2007 Recommendations
2009 Joint STEMI/PCI Focused Update
Recommendations Comments
Class IIa
1. It is reasonable to use a DES as an alternative to a
BMS for primary PCI in STEMI.11,105 (Level of
Evidence: B)*
New recommendation
Class IIb
2007 PCI Guideline Update, Table 16
1. A DES may be considered for clinical and anatomic settings
in which the effectiveness/safety profile appears favorable
but has not been fully confirmed by clinical trials. (Level of
Evidence: C)
1. A DES may be considered for clinical and anatomic
settings† in which the efficacy/safety profile appears
favorable.106–109 (Level of Evidence: B)
Modified recommendation (level of
evidence changed from C to B).
*Consideration for the use of stents (DES or BMS) in STEMI should include the ability of the patient to comply with prolonged dual-antiplatelet therapy, the bleeding
risk in patients undergoing chronic oral anticoagulation, and the possibility that the patient may need surgery during the ensuing year.28
†For example, small vessels, long lesions, or diabetes mellitus. This recommendation applies to primary and nonprimary PCI patients with STEMI.
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PCI Focused Update Section
9. Recommendation for Angiography in Patients
With Chronic Kidney Disease
(See Table 9.)
9.1. Angiography in Patients With Chronic
Kidney Disease
Patients with chronic kidney disease (CKD) with or without
diabetes who undergo angiography are at high risk for a
contrast-induced nephropathy (CIN). At issue is the selection
of a contrast agent to minimize this risk. The 2007 UA/
NSTEMI guideline recommended that in patients with
chronic kidney disease undergoing angiography, “isosmolar
contrast agents are indicated and are preferred (Level of
Evidence: A)” (p e112).97 In patients with CKD or CKD and
diabetes mellitus who are undergoing angiography, isosmolar
contrast material was shown to lessen the rise in creatinine.
This was based on evidence up to mid-2007 that suggested
that isosmolar agents also reduced the risk of CIN in both a
moderate-sized randomized clinical trial (RECOVER [Renal
Toxicity Evaluation and Comparison Between Visipaque
(Iodixanol) and Hexabrix (Ioxaglate) in Patients With Renal
Insufficiency Undergoing Coronary Angiography]) that com-
pared iodixanol with ioxaglate119 and a meta-analysis of 16
smaller, earlier clinical trials.120
However, in mid-2007, a major US randomized trial of
contrast agents in patients with CAD and an estimated
glomerular filtration rate of 20 to 59 mL/min who were
undergoing angiography, the CARE study, was published.
CARE compared the low-osmolar agent iopamidol and the
isosmolar agent iodixanol and found no difference in the
primary end point (serum creatinine increase of 0.5 mg/dL or
higher over baseline) between iopamidol (4.4%) and iodixa-
nol (6.7%, P0.39).19
Since then, several larger randomized trials have been
published that reported no difference in CIN when iodixanol
was compared with various other low-osmolar contrast media
(LOCM).19,121–123 These and other randomized trials compar-
ing isosmolar iodixanol with LOCM have been summarized
in 2 mutually supportive and complementary meta-analyses
involving 16 trials in 2763 patients124 and 25 trials in 3260
patients,125 respectively. When more recent trials were com-
bined with the older studies, trends in CIN favoring iodixanol
were no longer significant (summary RR 0.79; 95% CI 0.56
to 1.12; P0.29; summary RR 0.80; CI 0.61 to 1.04; P0.10,
respectively).124,125 However, subanalyses showed variations
in relative renal safety by specific LOCM: A reduction in CIN
was observed when iodixanol was compared with ioxaglate,
the only ionic LOCM (RR 0.58, CI 0.37 to 0.92, P0.02124),
and with iohexol, a nonionic LOCM (RR 0.19 to 0.38,
P0.01124,125), but no difference was noted in comparisons of
iodixanol with iopamidol, iopromide, or ioversal,124 and a
single trial favored iomeprol.123 A pooled comparison of
iodixanol with all nonionic LOCM other than iohexol indi-
cated equivalent safety (RR 0.97; CI 0.72 to 1.32,
P0.86125). Results were consistent regardless of ancillary
preventive therapies (hydration, acetylcysteine), route of
administration (intravenous or intra-arterial), age, sex, dose,
or preexisting CKD or diabetes. Of further interest, findings
were similar in the 8 studies (n1793 patients) performed in
the setting of coronary angiography.124
These more recent observations indicate that the CIN risk
of contrast media cannot be attributed to osmolarity alone, but
that ionicity and other and unknown characteristics of spe-
cific agents may play a role. Thus, the updated evidence base
suggests that the recommended choices of contrast media
during coronary angiography be expanded to either isosmolar
media or LOCM other than ioxaglate or iohexol.
10. Recommendations for Use of Fractional
Flow Reserve
(See Table 10.)
10.1. Fractional Flow Reserve
Coronary angiography is often performed in clinical situa-
tions in which preprocedural functional testing has not been
obtained. Additionally, in the setting of multivessel disease,
the need to treat individual stenosis is often difficult to
determine. Although revascularization of ischemia-producing
lesions improves patient outcomes, the clinical benefits of
revascularization of stenotic but non–ischemia-producing le-
sions are less clear. Intraprocedural assessment of the func-
tional significance of individual stenosis may help define the
optimal revascularization strategy.
The objective of the FAME trial20 was to compare clinical
outcomes after PCI on the basis of conventional angiographic
determination of lesion severity versus fractional flow reserve
(FFR) combined with angiography in patients with multivessel
disease. This prospective, randomized, multicenter trial included
1005 patients selected from 1905 screened patients at 20 medical
centers who were randomized to either angiography-guided or
FFR-guided (for lesions with FFR less than or equal to 0.80)
PCI. Before randomization, lesions that required PCI were
prespecified on the basis of the angiographic appearance. Pa-
tients assigned to angiography-guided PCI had all identified
lesions treated with DES, whereas those assigned to FFR-guided
PCI had only identified lesions with an FFR of 0.80 or less
Table 9. Recommendation for Angiography in Patients With Chronic Kidney Disease
2004/2005/2007 Recommendation: 2007 PCI
Guidelines Update, Table 9 2009 PCI Focused Update Recommendation Comments
Class I
2. In chronic kidney disease patients undergoing
angiography, isosmolar contrast agents are
indicated and are preferred. (Level of Evidence: A)
1. In patients with chronic kidney disease undergoing angiography
who are not undergoing chronic dialysis, either an isosmolar
contrast medium19,119 (Level of Evidence: A) or a
low-molecular-weight contrast medium other than ioxaglate or
iohexol is indicated.19 (Level of Evidence: B)
Modified recommendation
(changed text).
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treated with DES. The primary end point of the trial was the rate
of death, nonfatal MI, and repeat revascularization at 1 year.
No difference was evident in the number of intended
lesions to be treated per patient (2.70.9 versus 2.81.0,
P0.34) in the angiography- and FFR-guided groups, respec-
tively. In the FFR group, 37% of lesions had an FFR greater
than 0.80. Evaluation of ischemia, as defined by an FFR less
than 0.80, resulted in fewer lesions receiving stents (2.71.2
versus 1.91.3, P0.001). At 1 year, the composite event
rate was 18.3% in the angiography-guided group compared
with 13.2% in the FFR-guided group (P0.02).
The results of the FAME trial suggest that identification of
ischemia-producing lesions by use of systematic assessment
of FFR in patients undergoing multivessel PCI is associated
with improved clinical outcomes compared with angio-
graphic assessment alone. Further evidence is needed regard-
ing the added value of assessing FFR in lesions with greater
than 90% stenosis.
11. Recommendations for PCI for Unprotected
Left Main Coronary Artery Disease
(See Table 11.)
11.1. Unprotected Left Main Coronary Artery Disease
Although listed as a Class III indication in the 2003 guideline
on the management of chronic stable angina,145 PCI of an
unprotected left main coronary artery has increased in fre-
quency.146 Early studies (listed in Appendix 6) involved short
follow-up periods, which gave CABG a disadvantage, be-
cause the apparent benefits of surgery over PCI in other
settings have not typically been fully evident until 1 to 5 years
after the procedure. In the ACC/AHA/SCAI 2005 guideline
update for PCI, the performance of PCI for left main CAD is
given a Class III, Level of Evidence C recommendation if the
patient is eligible for CABG and a Class IIa, Level of
Evidence B recommendation for patients who are not eligible
for CABG. Thus, it has been recommended that CABG still
be considered the standard of care for left main CAD.147–149
Several studies comparing CABG to PCI, however, indi-
cated that the advantage of CABG consists primarily of fewer
repeat revascularizations.139,149–155 The study by Brener et
al156 indicates no significant mortality difference between
PCI and CABG after 3 years of follow-up. Longer-term
follow-up is needed.
The present focused update specifically addresses the
findings of SYNTAX, an unblinded, randomized clinical trial
that assigned patients with 3-vessel and/or left main CAD to
an initial treatment strategy of CABG or PCI.21 The primary
prespecified end point for the 1800 enrolled patients was the
composite of death, stroke, and myocardial revascularization
determined at 12 months. Prespecified stratification occurred
for diabetes mellitus and left main CAD. Ninety-seven
percent of CABG patients received at least 1 arterial graft.
In SYNTAX, for the subgroup with left main CAD, there
were no significant differences in the incidence of the
composite end point (death, MI, stroke, or repeat revascular-
ization) between the 2 groups (PCI 15.8% versus CABG
13.7%, P0.44), although rates of repeat revascularization
were higher (11.8% versus 6.5%, P0.02) and rates of stroke
were lower (0.3% versus 2.7%, P0.01) in the PCI group.21
Left main stented patients with limited CAD (lower SYNTAX
score) displayed a trend toward fewer adverse events at 12
months than did similar patients assigned to CABG. Specifi-
cally, MACE in patients with isolated left main CAD oc-
curred in 8.5% with CABG versus 7.1% with PCI, and in
13.2% with CABG versus 7.5% with PCI in patients with left
main CAD and disease of 1 other vessel. In contrast, MACE
with CABG versus PCI were numerically less frequent in
patients with disease of the left main coronary artery and
disease of 2 other vessels (14.4% versus 19.8%) and in
Table 10. Recommendations for Use of Fractional Flow Reserve
2004/2005/2007 Recommendation: 2005 PCI
Guideline, Section 5.6.2. 2009 PCI Focused Update Recommendations Comments
Class IIa
1. It is reasonable to use intracoronary physiologic
measurements (Doppler ultrasound, fractional
flow reserve) in the assessment of the effects of
intermediate coronary stenoses (30% to 70%
luminal narrowing) in patients with anginal
symptoms. Coronary pressure or Doppler
velocimetry may also be useful as an alternative
to performing noninvasive functional testing (eg,
when the functional study is absent or
ambiguous) to determine whether an
intervention is warranted. (Level of Evidence: B)
1. Coronary pressure (fractional flow reserve FFR) or Doppler
velocimetry can be useful to determine whether PCI of a
specific coronary lesion is warranted. FFR or Doppler
velocimetry can also be useful as an alternative to
performing noninvasive functional testing (eg, when the
functional study is absent or ambiguous) to determine
whether an intervention is warranted. It is reasonable to
use intracoronary physiological measurements (coronary
pressure FFR20,126–137 Level of Evidence: A or Doppler
velocimetry Level of Evidence: C) in the assessment of
the effects of intermediate coronary stenoses (30% to 70%
luminal narrowing) in patients with anginal symptoms.
Modified recommendation (level of
evidence changed from B to A
for FFR; C for Doppler).
Class III
1. Routine assessment with intracoronary
physiologic measurements such as Doppler
ultrasound or fractional flow reserve to assess
the severity of angiographic disease in patients
with a positive, unequivocal noninvasive
functional study is not recommended. (Level of
Evidence: C)
1. Routine assessment with intracoronary physiological
measurements such as coronary pressure (FFR) or Doppler
ultrasound to assess the severity of angiographic disease in
concordant vascular distribution in patients with angina and
a positive, unequivocal noninvasive functional study is not
recommended. (Level of Evidence: C)
Modified recommendation
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patients with both left main CAD and 3 other vessels
involved (15.4% versus 19.3%).21
These data from a post hoc subgroup analysis in SYNTAX
must be interpreted with caution for several reasons. The number
of patients with isolated left main (or left main plus single
vessel) CAD was relatively small, and the differences in out-
comes were not statistically significant. Furthermore, SYNTAX
reported outcomes at 1 year, and longer follow-up is needed
before left main PCI (in patients who are otherwise surgical
candidates) should become standard clinical practice. Moreover,
because the overall study did not reach its primary end point,
subset analyses are less robust; because noninferiority was not
proven in this cohort, specific information for each subgroup is
of an observational nature and is hypothesis-generating.
On the basis of the evidence in aggregate, prior to and
within the present focused update, the writing group has
modified the class of recommendation for PCI to unprotected
left main coronary from Class III to Class IIb, now citing the
Level of Evidence as B. The writing group noted 3 important
caveats in classifying unprotected left main CAD as a Class
IIb indication. First, patients undergoing PCI in cohort or
randomized studies represent merely a subset of all patients
with left main CAD. Because only certain left main coronary
lesions are amenable to PCI, the Class IIb indication is
intended to apply only to those left main lesions that are
suitable for PCI. The primary conclusion of SYNTAX is that
PCI failed to be shown to be noninferior to CABG in left
main and triple-vessel disease. Because patients in SYNTAX
with left main and 2- or 3-vessel disease compared with
patients with left main and no other vessel or 1-vessel disease
had higher rates of MACE, it is recommended that PCI to left
main lesions be limited to patients without significant mul-
tivessel disease. Second, because of the narrow margin for
error, operators undertaking PCI of left main coronary lesions
should be experienced and backed by highly competent
support staff and surgeons.157 Although routine use of intra-
vascular ultrasound has been advocated by some authors for
the evaluation of left main lesions, there is no definitive
evidence at present that this technique improves out-
comes.138,157 Finally, not all left main lesions respond equally
well to PCI. Bifurcation lesions are technically more chal-
lenging138 and have higher rates of restenosis.140,141,143,144 In
contrast, results of PCI of ostial or mid-body left main
coronary lesions more closely approximate the results of
CABG, even with respect to the need for subsequent proce-
dures.142 The best case for PCI as an alternative to CABG for
left main CAD is in ostial and mid-body lesions without
additional multivessel disease.
The writing group discussed the previous Class IIa recom-
mendation for follow-up between 2 and 6 months with
coronary angiography. They focused on the inability of
angiography to predict a situation that might be prone to
acute, sudden stent thrombosis, as well as the risk associated
with angiography in a patient who has undergone placement
of a left main stent. In view of these factors, the writing group
decided that the Class IIa recommendation for angiographic
follow-up should be omitted from the guidelines.
Table 11. Recommendations for PCI for Unprotected Left Main Coronary Artery Disease
2004/2005/2007 Recommendation 2009 PCI Focused Update Recommendations Comments
Class IIa
2005 PCI Guideline, Section 6.3.4.
1. It is reasonable that patients undergoing PCI to
unprotected left main coronary obstructions be
followed up with coronary angiography
between 2 and 6 months after PCI. (Level of
Evidence: C)
Deleted recommendation (no longer
recommended).
Class IIb
1. PCI of the left main coronary artery with stents as an
alternative to CABG may be considered in patients
with anatomic conditions that are associated with a
low risk of PCI procedural complications and clinical
conditions that predict an increased risk of adverse
surgical outcomes.*21,138,139 (Level of Evidence: B)
New recommendation
Class III
2005 PCI Guideline, Section 5.1
PCI is not recommended in patients with . . . 
f. Left main disease and eligibility for CABG.
(Level of Evidence: C)
2005 PCI Guideline, Sections 5.2, 5.3
PCI is not recommended in patients with . . . 
e. Left main disease and eligibility for CABG.
(Level of Evidence: C)
Modified recommendation (bullet “f” from
Section 5.1 and bullet “e” from
Sections 5.2. and 5.3. are no longer
current; see 2009 Class IIb
recommendation #1).
*Stenting for unprotected left main CAD is relatively more favorable for patients with isolated left main coronary artery lesions or left main coronary artery plus
single-vessel disease,21 for patients with ostial or mid left main coronary artery lesions,138,140–144 and for patients with factors (such as severe lung disease, prior
thoracic surgery, or poor bypass graft targets) that would make CABG a high-risk procedure or unlikely to be successful. Conversely, CABG surgery for unprotected
left main CAD may be relatively more favorable for patients with left main CAD plus multivessel disease,21 distal/bifurcation left main coronary artery lesions,138,140–144
or low surgical risk with a good chance of technical success.
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12. Recommendations for the Timing
of Angiography and Antiplatelet Therapy
in UA/NSTEMI
(See Table 12.)
12.1. Timing of Angiography
A routine invasive strategy in UA/NSTEMI patients with
high-risk features has been associated with improved out-
comes, but the optimal timing of intervention has not been
well established. Early intervention might prevent ischemic
events that could occur while the patient awaits a delayed
procedure. Alternatively, with intensive antithrombotic ther-
apy with a delay for up to a few days, procedure-related
complications might be avoided by intervening on a more
stable, “passivated” plaque. Although one study has sug-
gested greater benefit with relatively early intervention,106 the
evidence base for a definitive recommendation on timing is
weak. Thus, the question of when to intervene in UA/
NSTEMI has not been answered conclusively. Given this
uncertainty, the TIMACS investigators23 undertook a large,
multicenter randomized trial to determine whether a strategy
of early coronary angiography and intervention was superior
to a delayed strategy in patients with UA/NSTEMI assigned
to an invasive approach.
TIMACS randomly assigned 3031 non–ST-elevation ACS
patients to routine early intervention (coronary angiography
within 24 hours) or to delayed intervention (coronary angiogra-
phy at 36 hours or more). The primary outcome was the
composite of death, MI, or stroke at 6 months, and a prespecified
secondary outcome was death, MI, or refractory ischemia.23
Coronary angiography was performed at a median of 14 hours
in the early-intervention group and 50 hours in the delayed-
intervention group. At 6 months, 9.7% of patients in the
early-intervention group experienced a primary outcome versus
11.4% in the delayed-intervention group (HR 0.85; 95% CI 0.68
to 1.06; P0.15). Death, MI, or refractory ischemia was reduced
by 28% in favor of early intervention (9.6% versus 13.1%; HR
0.72; 95% CI 0.58 to 0.89; P0.002). Prespecified analyses
showed that early intervention improved the primary outcome in
the one third of patients at highest risk (HR 0.65; 95% CI 0.48
to 0.88), as determined by a GRACE (Global Registry of Acute
Coronary Events) risk score greater than 140, but not in the two
thirds at low to intermediate risk (HR 1.14; 95% CI 0.82 to 1.58;
P for heterogeneity0.01). There were no safety issues related
to early intervention; major bleeding occurred in 3.1% of
patients in the early invasive group and 3.5% in the delayed
invasive group.
Overall in TIMACS, early intervention trended to be
superior to delayed intervention in preventing the composite
of death, MI, or stroke (primary end point), but the difference
was not statistically significant.23 However, early intervention
reduced the composite of death, MI, or refractory ischemia
(the secondary end point) and, in high-risk patients, was
superior to a delayed invasive strategy. The trial was under-
powered to discern a clinically meaningful 15% advantage to
early invasive therapy for the primary end point, with
recruitment stopped at 3000 because of recruitment and
funding challenges. This provided a power of 80% to detect
a risk reduction of 28% in the primary end point. Subgroup
analysis (high-risk subset) of this overall negative trial was
not robust and must be viewed cautiously.
Taken together with the earlier ISAR-COOL (Intracoro-
nary Stenting With Antithrombotic Regimen Cooling Off)
study,106 the favorable secondary end-point results, the sub-
group analysis in patients at higher risk, and the lack of a
safety issue with early therapy, TIMACS suggests the fol-
lowing conclusions: an early invasive strategy within 12 to 24
hours (median 14 hours) is preferred in high-risk patients and
may be chosen in patients at low to intermediate risk at the
physician’s or institution’s preference (eg, efficiency and cost
savings), whereas a more delayed approach may be beneficial
in low- to intermediate-risk patients.23 In contrast, results
from the recent ABOARD (Angioplasty to Blunt the rise Of
troponin in Acute coronary syndromes Randomized for an
immediate or Delayed intervention) trial160 indicate that an
immediate invasive strategy (median time 1.1 hour) in UA/
NSTEMI is not associated with further incremental benefit.
Typically, early versus delayed angiography is defined
with reference to a 12- to 48-hour time window. The
ISAR-COOL study106 supports an earlier compared with a
more delayed time to angiography, but the data supporting
this general timing suggestion are limited.
12.2. Timing of GP IIb/IIIa Receptor Antagonist Therapy
in UA/NSTEMI Patients Undergoing Angiography
The optimal timing of initiation of GP IIb/IIIa receptor
antagonist therapy in patients with UA/NSTEMI (ie, whether
Table 12. Recommendations for the Timing of Angiography and Antiplatelet Therapy in UA/NSTEMI
2004/2005/2007
Recommendation 2009 PCI Focused Update Recommendations Comments
Class I
1. Patients with definite or likely UA/NSTEMI selected for an invasive approach should receive
dual-antiplatelet therapy.158,159 (Level of Evidence: A) Aspirin should be initiated on presentation.158,159
(Level of Evidence: A) Clopidogrel (before or at the time of PCI)158,159 (Level of Evidence: A) or
prasugrel (at the time of PCI)27 (Level of Evidence: B) is recommended as a second antiplatelet agent.
New recommendation
Class IIa
1. It is reasonable for initially stabilized high-risk patients with UA/NSTEMI* (GRACE Global Registry of
Acute Coronary Events risk score greater than 140) to undergo an early invasive strategy within 12
to 24 hours of admission. For patients not at high risk, an early invasive approach is also
reasonable.22,23 (Level of Evidence: B)
New recommendation
*Immediate catheterization/angiography is recommended for unstable patients.
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to administer therapy upstream on presentation or later at the
time of angiography/PCI) and the optimal application of this
therapy (ie, whether routine, selective, or provisional) have
not been resolved. The 2007 ACC/AHA Guidelines for the
Management of Patients With UA/NSTEMI recommend that
patients with definite or likely UA/NSTEMI selected for an
invasive approach should receive ASA and either clopidogrel
or a GP IIb/IIIa receptor antagonist before angiography
(Class I, Level of Evidence: A).97 They further state that it is
reasonable to initiate both clopidogrel and a GP IIb/IIIa
receptor antagonist, especially in the setting of delays to
angiography, high-risk features, or recurrent ischemic discom-
fort (Class IIa, Level of Evidence: B). The 2007 European
Society of Cardiology guidelines recommend early dual-
antiplatelet therapy with ASA and clopidogrel (Class I), with the
addition of a GP IIb/IIIa receptor antagonist for those patients
with the specific high-risk features of an elevated troponin level,
ST-segment depression, or diabetes (Class IIa).163
The EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in
Patients With Non–ST-Segment Elevation Acute Coronary Syn-
drome) trial22 tested the hypothesis that a strategy of early,
routine administration of the GP IIb/IIIa receptor antagonist
eptifibatide would be superior to delayed, provisional adminis-
tration in reducing ischemic complications among high-risk
patients. EARLY ACS enrolled 9492 non–ST-segment eleva-
tion ACS (UA/NSTEMI) patients who presented within 24
hours of an episode of ischemic rest discomfort and who were
assigned to an invasive treatment strategy no sooner than the
next calendar day (amended later to at least 12 hours but less
than 96 hours after randomization). Eligibility required at least 2 of
the following features: ST-segment depression or transient ST-
segment elevation, an elevated biomarker (creatine kinase-MB or
troponin), and age of 60 years or older (amended to include patients
50 to 59 years with known vascular disease). The key primary end
point was all-cause death, MI, recurrent ischemia that required
urgent revascularization, or thrombotic bailout at 96 hours. The key
secondary efficacy end point was all-cause death or MI within 30
days. Safety end points included major hemorrhage and transfu-
sions through 120 hours after randomization. The study was
powered to detect 22.5% and 15% relative reductions in the primary
and key secondary end points, respectively.
The primary end point occurred in 9.3% of patients in the
early therapy arm versus 10.0% of patients in the provisional
GP IIb/IIIa therapy arm (odds ratio 0.92; 95% CI 0.80 to 1.06;
P0.23). Secondary end-point event rates were 11.2% versus
12.3% (odds ratio 0.89; CI 0.79 to 1.01; P0.08). Early,
routine eptifibatide administration occurred at the cost of a
greater risk of TIMI major hemorrhage (2.6% versus 1.8%,
P0.02). Moderate and less severe bleeding also occurred
more commonly. Rates of red cell transfusion were 8.6% and
6.7%, respectively (P0.001).
EARLY ACS represents a large, carefully executed trial with
potentially important implications; however, these results are
best taken in the context of previous major trials. As a single
trial, EARLY ACS does not establish the superiority of early
versus delayed, provisional eptifibatide in non–ST-elevation
ACS. A trend toward fewer recurrent ischemic complications
was noted at 30 days, but this was counterbalanced by more
frequent episodes of bleeding and need for transfusions. Given
the use of eptifibatide at PCI (39% of patients in the delayed,
provisional group), EARLY ACS does not contradict the benefit
of GP IIb/IIIa therapy over placebo in UA/NSTEMI in previous
studies. Rather, its findings relate specifically to the timing of
such therapy and selective versus routine use.
In another similar study, ACUITY (Acute Catheterization
and Urgent Intervention Triage strategY), superiority of early
GP IIb/IIIa therapy also was not found, but investigators
could not exclude as much as a 29% benefit with GP IIb/IIIa
therapy nor show noninferiority of delayed administration. In
addition, drug exposure before angiography was much shorter
(4 hours), which might substantially diminish the opportunity
for differential efficacy.161
The results of the EARLY ACS study are similar to a
meta-analysis of 6 prior large, randomized trials of GP IIb/IIIa
therapy versus placebo in non–ST-elevation ACS in which an
invasive strategy was not mandated, which showed a relative
reduction in death/MI of 9% (CI 2% to 16%).162 In those patients
who underwent PCI, the RR reduction was a more robust 23%
(CI 8% to 36%). This finding also was consistent with EARLY
ACS. Both studies found no benefit in troponin-negative pa-
tients. The investigators ascribed the less than expected benefit
of early GP IIb/IIIa therapy in EARLY ACS to convergence of
eptifibatide use in the 2 arms at the time of PCI and more
aggressive contemporary cotherapies compared with earlier
studies, including frequent use of clopidogrel, low-molecular-
weight heparin, and statins. A further caution is the lack of
follow-up for several years.
Despite a lack of clarity from the overall and subgroup
results, an argument can be made against the routine upstream
use of GP IIb/IIIa therapy in all non–ST-elevation ACS
patients intended for an invasive strategy. In particular, those
with a normal baseline troponin level and those over the age
of 75 years, in whom there was no evidence for benefit but
who showed an increased risk of bleeding, might be ex-
cluded. On the other hand, findings in those with a positive
troponin at baseline and those with diabetes, although not
definitive in EARLY ACS alone, trend positively and are in
line with previous results. The EARLY ACS trial showed no
significant benefit in the composite outcome comparing early
versus delayed eptifibatide as defined by the study. Thus, at
this time, a high-risk group that would clearly benefit from
the early administration of eptifibatide upstream before car-
diac catheterization has not been identified. Early GP IIb/IIIa
therapy in patient groups continues to appear reasonable if
they are judged clinically to be at high risk of thrombotic
events relative to bleeding risk.
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Appendix 4. Dosing Table for Antiplatelet and Anticoagulant Therapy Discussed in This Focused Update to Support PCI in STEMI
During PCI
Comments: All Patients to Receive
ASA (162–325 mg)Drug*
Patient Received Initial Medical
Treatment (With an
Anticoagulant and/or
Fibrinolytic Therapy)
Patient Did Not Receive Initial Medical
Treatment (With an Anticoagulant
and/or Fibrinolytic Therapy)
Glycoprotein IIb/IIIa Receptor
Antagonists (Section 2)
Abciximab Of uncertain benefit LD of 0.25 mg/kg IV bolus
MD of 0.125 mcg/kg per minute
(maximum 10 mcg/min) (Class IIa,
LOE: A)
Continue for up to 12 hours at the
discretion of the physician.9,11
Eptifibatide Of uncertain benefit LD of 180 mcg/kg IV bolus followed 10
minutes later by second IV bolus of
180 mcg/kg
MD of 2.0 mcg/kg per minute, started
after first bolus; reduce infusion by
50% in patients with estimated
creatinine clearance 50 mL/min
(Class IIa, LOE: B)
Double bolus recommended to support
PCI in STEMI as the recommended
adult dosage of eptifibatide in
patients with normal renal
function.6,7
Infusion should be continued for 12 to
18 hours at the discretion of the
physician.9
Tirofiban Of uncertain benefit LD of 25 mcg/kg IV bolus
MD of IV infusion of 0.15 mcg/kg per
min; reduce rate of infusion by 50%
in patients with estimated creatinine
clearance 30 mL/min (Class IIa,
LOE: B)
Increased dosing over previous
recommendation.11,12
Continue for up to 18 hours at the
discretion of the physician.12
Thienopyridines (Section 3)
Clopidogrel† If 600 mg given orally, then no
additional treatment
A second LD of 300 mg may
be given orally to
supplement a prior LD of
300 mg (Class I, LOE: C)
LD 300–600 mg orally
MD of 75 mg orally per day (Class I,
LOE: C)
Optimum LD has not been established.
Dose for patients 75 years of age
has not been established.
There is a recommended duration of
therapy for all post-PCI patients
receiving a BMS or DES.
Period of withdrawal before surgery
should be at least 5 days.
(For full explanations, see footnote.)
Prasugrel‡ No data are available to guide
decision making
LD of 60 mg orally
MD of 10 mg orally per day (Class I,
LOE: B)
There is no clear need for treatment
with prasugrel before PCI.
MD of 5 mg orally per day in special
circumstances.
Special dosing for patients 60 kg or
75 years of age.
There is a recommended duration of
therapy for all post-PCI patients
receiving a DES.
Contraindicated for use in patients
with prior history of TIA or stroke.
(For full explanations, see footnote.)
Parenteral Anticoagulants
(Section 4)
Bivalirudin For patients who have received
UFH, wait 30 minutes, then
give 0.75 mg/kg bolus, then
1.75 mg/kg per hour
infusion (Class I, LOE: B)
0.75 mg/kg bolus, 1.75 mg/kg per hour
infusion
Bivalirudin may be used to support PCI
and STEMI with or without
previously administered UFH with
the addition of 600 mg of
clopidogrel.9 In STEMI patients
undergoing PCI who are at high risk
of bleeding, bivalirudin
anticoagulation is reasonable.9
(Continued)
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Appendix 4. Continued
During PCI
Comments: All Patients to Receive
ASA (162–325 mg)Drug*
Patient Received Initial Medical
Treatment (With an
Anticoagulant and/or
Fibrinolytic Therapy)
Patient Did Not Receive Initial Medical
Treatment (With an Anticoagulant
and/or Fibrinolytic Therapy)
UFH IV GP IIb/IIIa planned: target
ACT 200–250 seconds
No IV GP IIb/IIIa planned:
target ACT 250–300
seconds for HemoTec,
300–350 seconds for
Hemochron (Class I, LOE: C)
IV GP IIb/IIIa planned: 50–70 U/kg bolus
to achieve an ACT of 200–250
seconds
No IV GP IIb/IIIa planned: 70–100 U/kg
bolus to achieve target ACT of
250–300 seconds for HemoTec,
300–350 seconds for Hemochron
(Class I, LOE: C)
ACT indicates activated clotting time; BMS, bare-metal stent; CABG, coronary artery bypass graft; DES, drug-eluting stent; GP, glycoprotein; IV, intravenous; LD,
loading dose; LOE, level of evidence; MACE, major adverse cardiac events; MD, maintenance dose; PCI, percutaneous coronary intervention; STEMI, ST-elevation
myocardial infarction; TIA, transient ischemic attack; and UFH, unfractionated heparin.
*This list is in alphabetical order and is not meant to indicate a particular therapy preference. This drug table does not make recommendations for combinations
of listed drugs. It is only meant to indicate approved dosages if a drug is chosen for a given situation.
†The optimum LD of clopidogrel has not been established. Randomized trials establishing its efficacy and providing data on bleeding risks used an LD of 300 mg
orally followed by a daily oral dose of 75 mg.26,27 Higher oral LDs such as 600 mg or more than 900 mg36 of clopidogrel more rapidly inhibit platelet aggregation and
achieve a higher absolute level of inhibition of platelet aggregation, but the additive clinical efficacy and safety of higher oral LD have not been rigorously established.
For post-PCI patients receiving a DES, a daily MD should be given for at least 12 months unless the risk of bleeding outweighs the anticipated net benefit afforded
by a thienopyridine. For post-PCI patients receiving a BMS, an MD should be given for a minimum of 1 month28 and ideally up to 12 months (unless the risk of bleeding
outweighs the anticipated net benefit afforded by a thienopyridine; then it should be given for a minimum of 2 weeks). The necessity for giving an LD of clopidogrel
before PCI is driven by the pharmacokinetics of clopidogrel, for which a period of several hours is required to achieve desired levels of platelet inhibition. Patients
who have a reduced-function CYP2C19 allele have significantly lower levels of the active metabolite of clopidogrel, diminished platelet inhibition, and a higher rate
of MACE, including stent thrombosis.53 In STEMI patients taking clopidogrel for whom CABG is planned and can be delayed, it is reasonable to discontinue the
clopidogrel to allow for dissipation of the antiplatelet effect, unless the urgency for revascularization and/or the net benefit of clopidogrel outweighs the potential risks
of excess bleeding. The period of withdrawal should be at least 5 days in patients receiving clopidogrel.30 Clopidogrel LD after fibrinolytic therapy: For patients given
fibrin- and non–fibrin-specific fibrinolytic drugs who are undergoing PCI within 24 hours, 300 mg; for patients given a fibrin-specific fibrinolytic undergoing PCI after
more than 24 hours, 300 to 600 mg; for patients given a non–fibrin-specific fibrinolytic undergoing PCI between 24 and 48 hours, 300 mg; for patients given a
non–fibrin-specific fibrinolytic undergoing PCI after 48 hours, 300 to 600 mg.
‡Patients weighing60 kg have an increased exposure to the active metabolite of prasugrel and an increased risk of bleeding on a 10-mg once-daily MD. Consider
lowering the MD to 5 mg in patients who weigh 60 kg. The effectiveness and safety of the 5-mg dose have not been studied prospectively. For post-PCI patients
receiving a DES, a daily MD should be given for at least 12 and up to 15 months unless the risk of bleeding outweighs the anticipated net benefit afforded by a
thienopyridine. Do not use prasugrel in patients with active pathological bleeding or a history of TIA or stroke. In patients 75 years of age, prasugrel is generally
not recommended because of the increased risk of fatal and intracranial bleeding and uncertain benefit, except in high-risk situations (patients with diabetes or a
history of prior MI) for which its effect appears to be greater and its use may be considered. Do not start prasugrel in patients likely to undergo urgent CABG. When
possible, discontinue prasugrel at least 7 days before any surgery. Additional risk factors for bleeding include body weight 60 kg, propensity to bleed, concomitant
use of medications that increase the risk of bleeding (eg, warfarin, heparin, fibrinolytic therapy, or chronic use of nonsteroidal antiinflammatory drugs).
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Appendix 6. Outcomes of PCI Versus CABG for Unprotected Left Main Coronary Artery Disease
Reference, Year Type of Study, Years of Recruitment PCI/CABG Short-Term Results Long-Term Results
Chieffo et al,141 2006 Cohort, 2002–2004 107/142 In-hospital outcomes for PCI versus CABG:
Death: 0% versus 2.1%; PNS
MI: 9.3% versus 26.1%; P0.0009
Stroke: 0% versus 2%; PNS
1-Year adjusted ORs for PCI versus CABG:
Death or MI: 0.26; 95% CI 0.078–0.597; P0.0005
Death, MI, or stroke: 0.385; 95% CI 0.180–0.819;
P0.01
Revascularization: 4.2; 95% CI 1.486–14.549; P0.005
Lee et al,151 2006 Cohort, 2003–2005 50/123 30-Day outcomes for PCI versus CABG:
Death: 2% versus 5%; PNS
MI: 0% versus 2%; PNS
Stroke: 0% versus 8%; P0.03
Death/MI/stroke/revascularization: 17%
versus 2%; P0.01
1-Year follow-up for PCI versus CABG:
Death: 4% versus 15%; P0.2
Death, MI, stroke: 4% versus 21%; HR4.4; 95% CI
1.0–18.6; P0.03
Revascularization: 13.3% versus 5.5%; P0.2
Palmerini et al,152 2006 Cohort, 2002–2005 157/154 30-Day outcomes for PCI versus CABG:
Death: 3.2% versus 4.5%; PNS
MI: 4.5% versus 1.9%; PNS
Revascularization: 0.6% versus 0.6%;
PNS
1- to 2-Year follow-up for PCI and CABG:
Death: 13.4% versus 12.3%; 95% CI 0.51–1.77;
P0.8
MI: 8.3% versus 4.5%; 95% CI 0.21–1.32; P0.17
Revascularization: 2.6% versus 25.5%; 95% CI
0.03–0.23; P0.0001
Buszman et al,150 2008 Randomized, 2001–2004 52/53 30-Day outcomes for PCI versus CABG:
Death: 0% versus 0%
MI: 2% versus 4%; PNS
MACE: 2% versus 14%; 95% CI
0.79–0.99; P0.03
1-Year follow-up for PCI versus CABG:
Death: 2% versus 8%; PNS
MI: 2% versus 6%; PNS
Revascularization: 30% versus 10%; 95% CI
1.05–1.54; P0.01
MACE: 32% versus 26%; 95% CI 0.85–1.38; PNS
(Continued)
Appendix 5. Triage and Transfer for PCI
STEMI patient 
who is a candidate 
for reperfusion
Initially seen at a 
PCI capable 
facility
Send to Cath Lab 
for primary PCI
(Class I, LOE: A)
Initially seen at a 
non-PCI capable 
facility
Transfer for 
primary PCI 
(Class I, LOE: A)
HIGH RISK
Transfer to a PCI 
facility is 
reasonable for 
early diagnostic 
angio and possible 
PCI or CABG 
(Class IIa, LOE: B)
High-risk patients 
as defined by 
2007 STEMI 
Focused Update 
should undergo 
cath 
(Class I, LOE: B)
NOT HIGH RISK
Transfer to a PCI 
facility may be 
considered
(Class IIb, LOE: 
C), especially if 
ischemic
symptoms persist 
and failure to 
reperfuse is 
suspectedMedical
therapy only
PCI CABG
Preparatory antithrombotic (anticoagulant 
plus antiplatelet) regimen
Selection of 
reperfusion strategy*
At PCI 
facility, 
evaluate 
for timing 
of 
diagnostic
angio
Diagnostic angio
Initial treatment with 
fibrinolytic therapy
(Class I, LOE: A)
Angio indicates angiography; CABG, coronary artery bypass graft surgery; Cath Lab, catheterization laboratory; LOE, level of evidence; PCI, percutaneous coronary
intervention; and STEMI, ST-elevation myocardial infarction.
Each community and each facility in that community should have an agreed-on plan for how STEMI patients are to be treated that includes which hospitals should
receive STEMI patients from emergency medical services units capable of obtaining diagnostic electrocardiograms, management at the initial receiving hospital, and
written criteria and agreements for expeditious transfer of patients from non–PCI-capable to PCI-capable facilities. Consideration should be given to initiating a
preparatory pharmacological regimen as soon as possible in preparation for and during patient transfer to the catheterization laboratory. The optimal regimen is not
yet established, although published studies (see text for details) have used various combinations of the following: anticoagulant, oral antiplatelet agents, intravenous
antiplatelet.
*Time since onset of symptoms; risk of STEMI; risks associated with fibrinolytic therapy; time required for transport to a skilled PCI laboratory.
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Reference, Year Type of Study, Years of Recruitment PCI/CABG Short-Term Results Long-Term Results
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Correction
In the article by Kushner et al, “2009 Focused Updates: ACC/AHA Guidelines for the
Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline
and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Inter-
vention (Updating the 2005 Guideline and 2007 Focused Update): A Report of the American
College of Cardiology Foundation/American Heart Association Task Force on Practice Guide-
lines,” which published ahead of print on November 18, 2009, and appeared in the December 1,
2009, issue of the journal (Circulation. 2009;120:2271–2306), a correction is needed.
On page 2299, in Appendix 4, in the tirofiban row, in the third column, the phrase “MD of IV
infusion of 0.1 mcg/kg per min;” should be changed to “MD of IV infusion of 0.15 mcg/kg per min;”
for the dosing to read correctly.
This correction has been made to the current online version of the article, which is available at
http://circ.ahajournals.org/cgi/content/full/120/22/2271.
DOI: 10.1161/CIR.0b013e3181d7a65e
(Circulation. 2010;121:e257.)
© 2010 American Heart Association, Inc.
Circulation is available at http://circ.ahajournals.org
e257
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Report of the American College of Cardiology Foundation/American Heart Association 
Task Force on Practice Guidelines,” which published ahead of print on November 18, 
2009, and appeared in the December 1, 2009, issue of the journal (Circulation. 
2009;120:2271–2306), a correction is needed. 
 
On page 2299, in Appendix 4, in the tirofiban row, in the third column, the phrase “MD 
of IV infusion of 0.1 mcg/kg per min” should be changed to “MD of IV infusion of 0.15 
mcg/kg per min” for the dosing to read correctly. 
